Package | Version | Identity | Name/Title | Status | Date |
---|
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.12  | Wound exudate color value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.13  | Exudate odor value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.14  | Wound anatomic location value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.16  | Skin temperature value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.17  | Skin color enumerated value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.18  | Skin turgor value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.19  | Skin and mucous membrane integrity value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.2  | Periwound condition value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.20  | Skin moisture value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.3  | Wound Type Etiology value set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.4  | Wound episode value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.6  | Wound bed appearance value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.60  | Wound type reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.7  | Wound bed color value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.74  | Nonverbal pain indicators reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.76  | Pain associated signs and symptoms reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.77  | Pain body location reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.8  | Wound edge description value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.80  | Pain quality reference set | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.81  | Pain speed of onset reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.9  | Presence absence value set (foundation metadata concept) | active | 2018-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.1  | Common drug substances for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.2  | Common drug classes for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.3  | Common dietary substances for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.4  | Common environmental substances for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.5  | Common refutations for substance causes for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.7  | Common substances for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.8  | Common substances for allergy and intolerance documentation including refutations | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.10  | NHSNCriterionOfDiagnosisCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.11  | NHSNCriterionOfDiagnosisCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.12  | NHSNInfectionConditionCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.13  | NHSNInfectionConditionCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.14  | NHSNInfectionTypeCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.15  | NHSNInfectionTypeCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.16  | NHSNInfectionFirstReportedSource(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.17  | NHSNInfectionFirstReportedSource(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.18  | NHSNLOS/MENDischargeDisposition(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.19  | NHSNLOS/MENDischargeDisposition(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.20  | NHSNPopulationSummaryReportTypeCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.21  | NHSNPopulationSummaryReportTypeCode(LOINC) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.22  | NHSNSameDayOutcomeMeasure(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.23  | NHSNSameDayOutcomeMeasure(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.24  | NHSNSignificantPathogenCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.25  | NHSNSignificantPathogenCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.26  | NHSNSpinalFusionApproachCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.27  | NHSNSpinalFusionApproachCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.28  | NHSNVascularAccessTypeCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.29  | NHSNVascularAccessTypeCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.30  | NHSNVascularSpecimenCollectionSite(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.31  | NHSNVascularSpecimenCollectionSite(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.38  | Blood Glucose Laboratory and Point of Care Tests | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.58  | Diabetes Medications | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.6  | NHSNPathogenCodeARO | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.62  | Lab Tests for Clostridioides difficile | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.63  | Bacterial and Fungal Blood Culture Tests | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.7  | NHSNRoleOfPerformerCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.74  | Enteral Medication Route | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.75  | Intravenous Medication Route | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.76  | Fidaxomicin | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.77  | Vancomycin | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.78  | Metronidazole | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.79  | Fidaxomicin, Vancomycin, and Metronidazole | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.8  | NHSNRoleOfPerformerCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.85  | Baloxavir | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.86  | Peramivir | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.87  | Zanamivir | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.88  | Digestive, Intramuscular, Intravenous Route of Administration | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.89  | Maternal Diagnoses | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.9  | NHSNRoleOfPerformerCode(HealthCareProviderTaxonomy) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.90  | NHSN LTC AU Antimicrobial Agents | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.91  | Long Term Care Discharge Disposition | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.94  | NHSNNeurogenicBladder | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.95  | NHSNSpinalCordInjury | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1139  | S4G Hyperlipidemia | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1291  | S4G Cardiomyopathy | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1292  | S4G Tricuspid valve disorder | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1293  | S4G Pompe disease | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1294  | S4G Malignant hyperthermia | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1295  | S4G Malignancy | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1297  | S4G Intestinal polyp | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1298  | S4G Hamartoma | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1299  | S4G Diabetes mellitus | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1300  | S4G Muscular dystrophy and weakness | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1325  | S4G Hamartoma and S4G Intestinal Polyp | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1326  | S4G Malignancy and S4G Intestinal Polyp | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1344  | Tests for Neisseria gonorrhoeae of unspecified site reported by presence | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1352  | Body weight | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1354  | Cefixime preparations for oral administration | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1358  | Beta lactam medicinal product SNOMED | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1370  | Beta lactam ingredients for allergy determination RXNORM | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.147  | SCIP Major Surgical Procedure | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.158  | Multiple Myeloma Regimen Drugs | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.226  | Opioids, All | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3483  | Financial Insecurity Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3484  | Food Insecurity Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3485  | Health Literacy Screening Assessments Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3486  | Homelessness Screening Assessments Questions | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3487  | Housing Instability Screening Assessments Questions | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3488  | Less Than High School Education Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3519  | Health Insurance Coverage Status Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3520  | Inadequate Housing Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.393  | Hypoglycemics Severe Hypoglycemia | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.394  | Hypoglycemics Treatment Medications | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4436  | Gentamicin medications | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4437  | Azithromycin medications | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4448  | Lidocaine | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4466  | Pharyngeal specimens | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4467  | Urogenital & Anorectal Specimens | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4469  | Cabotegravir Injectable Products | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4470  | Emtricitabine oral for HIV PrEP | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4474  | HIV Laboratory Based Tests | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4502  | Ceftriaxone all code types | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.491  | Medium Dose ICS Formoterol Preparations | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495  | ICS LABA LAMA Preparations | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.788  | Social Determinants of Health Conditions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.789  | Social Determinants of Health Procedures | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.790  | Social Determinants of Health Service Requests | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.93  | CPIC RxNORM abacavir SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.94  | CPIC RxNORM allopurinol SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.95  | CPIC RxNORM amitriptyline SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.96  | CPIC RxNORM atazanavir SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.97  | CPIC RxNORM atomoxetine SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.99  | CPIC RxNORM capecitabine SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.1  | Mechanical Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.10  | Surgical Site Bleeding and Other Surgical Site Complications | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.11  | Procedures Resulted From Surgical Site Bleeding and Other Surgical Site Complications | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.12  | Opioid (Oral Tablets and Patches only) | active | 2019-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.13  | Comorbidity Risk Factors | active | 2020-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.14  | Treatment of Hemorrhage or Hematoma | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.15  | General Surgery | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.17  | Coagulation Disorder Conditions | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.18  | Acute Respiratory Failure | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.19  | Anticoagulant Medications | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.2  | Fracture Exclusions For Hip And Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.20  | Anticoagulant Medications, Oral | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.21  | Anticoagulant Medications, Injection | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.28  | Active Bleeding | active | 2020-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.29  | Fall Risk Increasing Drugs (FRIDs) | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.3  | Pulmonary Embolism Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.30  | Fall Risk Factors | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.32  | Total Hip Arthroplasty Surgery | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.33  | Total Knee Arthroplasty Surgery | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.34  | AbnormalityOfGaitAndMobility | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.35  | Assymetry Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.36  | Hemiplegia Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.37  | Leg Weakness Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.38  | Osteopenia Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.39  | Stroke Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.4  | Sepsis Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.40  | Vestibular Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.41  | TricyclicAntidepressants | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.42  | Benzodiazepines | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.43  | LoopDiuretics | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.44  | Antiepileptics | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.45  | Antipsychotics | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.46  | Opioid Medications | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.47  | Imaging Related to VTE | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.48  | Anticoagulant Medication | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.49  | VTE Diagnoses | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.5  | Nonprimary Total Hip, Total Knee Replacement | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.50  | Bisphosphonate Therapy | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.51  | VTE Symptoms | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.52  | Oncology Critical Care Units | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.53  | Provider Types | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.56  | FOBT_Lab | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.57  | Colorectal Screening | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.58  | Screening Mammogram (CPT) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.59  | Screening Mammogram (LOINC) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.6  | Pneumonia Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.60  | Screening Mammogram (SNOMEDCT) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.61  | Screening Mammogram (Grouping) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.62  | Diagnostic Mammography (CPT) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.63  | Diagnostic Mammography (LOINC) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.64  | Diagnostic Mammography (SNOMEDCT) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.65  | Diagnostic Mammography | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.66  | Breast Cancer Biopsy and Surgical Excision | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.67  | BI_RADS Categories 0, 4, and 5 | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.68  | BI_RADS Categories 1, 2, and 3 | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.7  | Malignant Neoplasm Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.8  | Periprosthetic Joint Infection/Wound Infection and Other Wound Complications | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.9  | Procedures Resulted From Periprosthetic Joint Infection/Wound Infections | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.101  | Local Anesthetics | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.102  | Ophthalmic Epinephrines | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.103  | Inhaled Epinephrines | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.104  | Clopidogrels | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.105  | Cytochrome P450 2C19 inhibitors | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.106  | Cytochrome P450 2C9 inhibitors | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.107  | Aspirin Ingredient and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.109  | Oral Anticoagulant Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.110  | Corticosteroid Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.111  | Antidepressant Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.112  | PPI and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.113  | Antiplatelet Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.114  | NSAIDs Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.115  | Kratom containing compounds | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.117  | Clopidogrel Ingredients and Risk of GI Bleeding | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.121  | Gastrointestinal bleeding episode and Risk of GI Bleeding 1 | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.122  | Gastrointestinal bleeding episode and Risk of GI Bleeding 2 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.123  | Gastrointestinal bleeding episode and Risk of GI Bleeding | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.24  | Oxycodones | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1217.2  | TESTSemanticBitsValueSet | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.1  | Bronchiectasis Disorder SNOMED | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.10  | Interstitial Lung Disease ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.100  | Occupational Therapy Procedure HCPCS | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.101  | Occupational Therapy Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.102  | Speech Language Therapy Procedure HCPCS | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.103  | Speech Language Therapy Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.104  | Home Health Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.105  | Intermittent Skilled Nursing Home Health Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.106  | pH, Hematocrit, Partial Pressure Carbon Dioxide, Partial Pressure Oxygen or Bicarbonate Laboratory Test for Breathing Assistance Device Evaluation Excluding Oxygen Saturation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.107  | Breathing Test Procedure During Sleep | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.108  | Ambulance Transport Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.109  | Prefabricated Spinal Orthotic Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.11  | Interstitial Lung Disease SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.110  | Custom Fitted Spinal Orthotic Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.111  | Custom Fabricated Spinal Orthotic Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.112  | Orthotic Device Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.113  | Spinal Orthotic Device or Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.115  | Spine or Neck Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.116  | Spine or Neck Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.117  | Spine or Neck Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.118  | Total Electric Hospital Bed Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.119  | Hypoventilation Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.12  | Interstitial Lung Disease | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.120  | Hypoventilation Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.121  | Hypoventilation Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.122  | Respiratory Assist Device Qualifying Condition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.123  | Apnea Hypopnea Index Rate Measurement | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.124  | Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC) Measurement | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.125  | Maximal Inspiratory Pressure Measurement | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.126  | Forced Vital Capacity (FVC) Measurement by Spirometry | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.127  | Oxygen Saturation Measurement At Rest | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.128  | Respiratory Assist Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.129  | Respiratory Assist Device Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.13  | Cystic Fibrosis Lung Disease ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.130  | Home Oxygen Therapy Accessory | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.131  | Forced Vital Capacity (FVC) Measurement Prediction | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.132  | Oxygen Saturation Laboratory Test and Setting for Breathing Assistance Device Evaluation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.133  | Respiratory Disturbance Index | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.134  | Sleep Related Symptom for Positive Airway Pressure Device Use Evaluation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.135  | Past Medical History Condition Related to Need for Positive Airway Pressure Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.136  | Home or Facility Care Location | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.137  | Fracture of Bone Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.138  | Fracture of Bone Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.139  | Fracture of Bone Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.14  | Cystic Fibrosis Lung Disease SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.140  | Severe Obesity Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.141  | Severe Obesity Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.142  | Severe Obesity Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.143  | Transfer from Bed Impairment SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.144  | Bed Confinement Impairment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.145  | Transfer from Bed Impairment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.146  | Ability to Safely Sit in Chair or Wheelchair Impairment SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.147  | Mobility Impairment or Fall From Chair ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.148  | Ability to Safely Sit in Chair or Wheelchair Impairment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.149  | Fall or Fall Risk from Wheelchair or Stretcher SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.15  | Cystic Fibrosis Lung Disease | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.150  | Fall or Fall Risk from Wheelchair or Scooter ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.152  | Muscle, Tendon or Joint Contracture Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.153  | Muscle, Tendon or Joint Contracture Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.154  | Muscle, Tendon or Joint Contracture Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.155  | Muscle Weakness or Myasthenia Gravis Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.156  | Muscle Weakness or Myasthenia Gravis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.158  | Myocardial Infarction Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.159  | Myocardial Infarction Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.16  | Neoplasm of Lung or Trachea Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.160  | Myocardial Infarction Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.161  | Amputation Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.162  | Amputation Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.164  | Lower Extremity Deep Vein Thrombosis Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.165  | Lower Extremity Deep Vein Thrombosis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.167  | Spinal Cord Injury or Paralysis Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.168  | Spinal Cord Injury or Paralysis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.169  | Spinal Cord Injury or Paralysis Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.17  | Neoplasm of Lung or Trachea Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.170  | Demyelinating Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.171  | Demyelinating Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.172  | Demyelinating Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.173  | Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.174  | Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.176  | Wound Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.177  | Wound Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.178  | Wound Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.179  | Danger to Self or Others Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.18  | Neoplasm of Lung or Trachea Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.180  | Danger to Self or Others Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.181  | Danger to Self or Others Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.182  | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.183  | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.184  | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.185  | Pain on Movement or Joint Pain Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.186  | Pain in Joint Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.187  | Pain on Movement or Joint Pain Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.188  | Non Emergency Ambulance Transport Reason | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.189  | Osteoarthritis Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.19  | Secondary Erythrocytosis Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.190  | Osteoarthritis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.191  | Osteoarthritis Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.192  | Immunosuppressive Medication RxNorm | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.193  | Medication Supporting Immunosupressive Medication RxNorm | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.194  | Non Emergency Ambulance Transport Qualifying Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.197  | Turalio | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.198  | Hepatic Medical History | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.2  | Bronchiectasis Disorder ICD10CM | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.20  | Secondary Erythrocytosis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.21  | Secondary Erythrocytosis Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.22  | Acute or Chronic Heart Failure Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.23  | Acute or Chronic Heart Failure Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.24  | Acute or Chronic Heart Failure Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.25  | Home Oxygen Therapy Qualifying Condition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.26  | Device Use Patient Activity Level | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.27  | Portable Liquid Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.28  | Stationary Liquid Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.29  | Sleep Apnea or Breathing Related Sleep Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.3  | Bronchiectasis Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.30  | Sleep Apnea or Breathing Related Sleep Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.31  | Sleep Apnea or Breathing Related Sleep Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.32  | Positive Airway Pressure Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.33  | Diabetes Mellitus Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.34  | Diabetes Mellitus Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.35  | Diabetes Mellitus Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.36  | Restrictive Lung Disease SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.37  | Restrictive Lung Disease ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.38  | Restrictive Lung Disease | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.39  | Chest Wall Deformity Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.4  | Chronic Obstructive Lung Disease (COPD) ICD10CM | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.40  | Chest Wall Deformity Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.41  | Chest Wall Deformity Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.42  | Motor Neuron Disease or Spinal Muscular Atrophy Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.43  | Motor Neuron Disease or Spinal Muscular Atrophy Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.44  | Motor Neuron Disease or Spinal Muscular Atrophy Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.45  | Chronic Respiratory Failure Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.46  | Chronic Respiratory Failure Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.47  | Chronic Respiratory Failure Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.48  | Ventilator Therapy Qualifying Condition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.49  | Ventilator Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.5  | Chronic Obstructive Lung Disease SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.50  | Fixed Height Hospital Bed Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.51  | Variable Height Hospital Bed Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.52  | Semi electric Hospital Bed Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.53  | Heavy Duty Extra Wide Hospital Bed Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.54  | Extra Heavy Duty Hospital Bed Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.55  | Hospital Bed Trapeze Accessory Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.56  | Hospital Bed Cradle Accessory Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.57  | Hospital Bed Side Rail or Safety Enclosure Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.58  | Hospital Bed Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.59  | Intermittent Urinary Catheter or Urological Supply for Intermittent Urinary Catheter Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.6  | Chronic Obstructive Lung Disease (COPD) | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.60  | Indwelling Urinary Catheter Supply or Urological Supply for Indwelling Urinary Catheter Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.61  | Urinary Collection and Irrigation System Device or Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.62  | External Catheter or Urinary Collection Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.63  | Miscellaneous Urinary Catheter Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.64  | Urinary Incontinence Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.65  | Urinary Incontinence ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.66  | Urinary Incontinence Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.67  | Chronic Urinary Retention Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.68  | Urinary Retention Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.69  | Chronic Urinary Retention Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.7  | Hypoxemia Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.70  | Urinary Incontinence or Chronic Urinary Retention Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.72  | Portable Compressed Gas Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.73  | Stationary Oxygen Concentrator Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.74  | Compressed Gas Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.75  | Stationary Compressed Gas Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.76  | Portable Oxygen Concentrator Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.77  | Liquid Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.78  | Oxygen Concentrator Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.79  | Portable Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.8  | Hypoxemia Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.80  | Stationary Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.81  | Organ Transplant History Significant to Immunosuppressive Therapy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.82  | Immunosuppressive Medication HCPCS | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.83  | Medication Supporting Immunosuppressive Medication HCPCS | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.84  | Home Blood Glucose Monitor Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.85  | Insulin Medication | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.86  | Hyperglycemia or Hypoglycemia Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.87  | Hyperglycemia or Hypoglycemia Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.88  | Hyperglycemia or Hypoglycemia Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.89  | Diabetic Test Strip or Lancet Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.9  | Hypoxemia Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.90  | Organ Transplant Procedure Significant to Immunosuppressive Therapy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.91  | Pulmonary Hypertension Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.92  | Pulmonary Hypertension Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.93  | Pulmonary Hypertension Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.94  | Laboratory Test for Home Glucose Monitor Evaluation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.95  | Physical Therapy Procedure SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.96  | Occupational Therapy Procedure SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.97  | Speech Language Therapy Procedure SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.98  | Physical Therapy Procedure HCPCS | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.99  | Physical Therapy Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.135  | Last Menstrual Period (LMP) | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.146  | Abortion, All (ICD 10 CM) | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.149  | Abortion, All (SNOMED CT) | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.150  | Abortion, All | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.151  | Abortion, All (CPT) | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.152  | Abortion, 1st Trimester | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.153  | Abortion, 2nd Trimester | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.154  | Abortion, 2nd Trimester | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.155  | Abortion, 3rd Trimester | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.156  | Abortion, Elective | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.157  | Abortion, Elective | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.158  | Abortion, Failed Attempt | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.159  | Abortion, Induced | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.160  | Abortion, Induced | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.161  | Abortion, Induced | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.162  | Abortion, Medical Management | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.163  | Abortion, Medical Management | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.164  | Abortion, Medical Management | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.165  | Abortion, Elective | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.166  | Abortion, Surgical Management | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.167  | Abortion, Surgical Management | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.168  | Abortion, Surgical Management | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.169  | Abortion, Spontaneous / Miscarriage | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.170  | Abortion, Spontaneous / Miscarriage | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.171  | Abortion, Spontaneous / Miscarriage | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.172  | Contraception, Counseling | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.173  | Contraception, Counseling | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.174  | Contraception, Counseling | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.175  | Contraception, Counseling | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.176  | Methotrexate Injection | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.177  | Mifepristone | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.178  | Misoprostol | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.179  | Abortion Medications | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.180  | Contraception, Surveillance | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.181  | Contraception, Surveillance | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.182  | Contraception, Surveillance | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.183  | Clomiphene (Selective Estrogen Receptor Modulator / SERM) | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.184  | Letrozole (Aromatase inhibitor) | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.185  | Infertility, Female Medications | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.186  | Infertility, Female | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.187  | Infertility, Female | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.188  | Infertility, Female | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.189  | Infertility, Male | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.190  | Infertility, Male | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.191  | Infertility, Male | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.192  | Infertility, All | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.193  | Gender Dysphoria | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.194  | Gender Identity | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.195  | Intersex Surgery, History | active | 2024-04 |
us.nlm.vsac | R4 | http://cts | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1540  | Coronary Revascularization History | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1541  | Heart Failure Diagnosis SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1542  | Heart Failure Diagnosis ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1543  | Heart Failure Diagnosis | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1547  | Hypertension, Primary and Secondary Diagnosis | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1548  | Cerebrovascular Disease Diagnosis SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1549  | Cerebrovascular Disease Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.155  | Bone Density | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1550  | Migraine Diagnosis SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1551  | Migraine Diagnosis ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1552  | Migraine Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1553  | Chronic Tension type Headache Diagnosis SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1554  | Chronic Tension type Headache Diagnosis ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1555  | Chronic Tension type Headache Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1556  | Low Back Pain SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1557  | Low Back Pain ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1558  | Low Back Pain | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1559  | Metabolic Syndrome Diagnosis SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.156  | Bone Survey X Rays | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1560  | Metabolic Syndrome Diagnosis ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1561  | Metabolic Syndrome Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1562  | Hypertension, Persistent ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1563  | Hypertension, Persistent | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1564  | Pregnancy SCT | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1565  | Pregnancy ICD10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1566  | Pregnancy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1568  | Low Density Lipoprotein | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1569  | Physical findings of the abdomen | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.157  | Chronic Kidney Disease All Stages (1 through 5) SNOMED | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1571  | Chest US | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1572  | Sleep Disorder Assessment | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1573  | Cerebral Spinal Fluid (CSF) Analysis | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1574  | Comprehensive Metabolic Panel (CMP) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1575  | Arterial Blood Gas (ABG) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1576  | Coagulation Assay (PT, aPTT, Fibrinogen) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1577  | D Dimer Test | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1578  | Procalcitonin in Blood, Serum, or Plasma | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1579  | Creatine Kinase (CK, CK MB) in Blood, Serum, or Plasma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.158  | Chronic Kidney Disease All Stages (1 through 5) ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1580  | COVID 19 (SARS CoV 2), SARS CoV, Influenza virus A and B Tests | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1581  | Microorganisms Detection by Blood Culture | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1582  | Microorganisms Detection by Sputum Culture | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1583  | Cystography | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1584  | Cognitive Health Related Questionnaire Panel Codes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1585  | Alcohol Use Related Questionnaire Panel Codes | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1586  | Functional Status Related Questionnaire Panel Codes | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1587  | Kidney Disease Related Questionnaire Panel Codes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1588  | Long Covid Related Questionnaire Panel Codes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1589  | Nutrition Status Related Questionnaire Panel Codes | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.159  | Chronic Kidney Disease All Stages (1 through 5) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1590  | Pain Perception Related Questionnaire Panel Codes | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1591  | Patient Goal Related Questionnaire Panel Codes | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1592  | Social Determinant of Health Related Questionnaire Panel Codes | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1593  | Covid 19 Related Health Questionnaire Panel Codes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1594  | Caregiver Considerations Related Questionnaire Panel Codes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1595  | Acute COVID 19 Diagnosis SCT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1597  | Drugs of Abuse Screen | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1598  | Criminal Justice Involvement or Incarceration History | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1599  | Cardiomyopathy Diagnosis SCT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1600  | Cardiomyopathy Diagnosis ICD10 | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1601  | Atherosclerotic Cardiovascular Disease SCT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1602  | Neuropathy Diagnosis ICD10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1603  | Neuropathy Diagnosis SCT | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1605  | Left Ventricular Hypertrophy ICD10 | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1606  | Left Ventricular Hypertrophy | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1607  | Alanine Aminotransferase (ALT) in Blood, Plasma, or Serum | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1608  | Aspartate Aminotransferase (AST) in Blood, Plasma, or Serum | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1609  | Erythrocyte Sedimentation Rate (ESR) in Blood | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1610  | Oxygen Saturation in Blood | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.176  | Urine Sediment | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.179  | Estimated Glomerular Filtration Rate (eGFR) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.22  | Alcohol Use Disorder SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.23  | Alcohol Use Disorder ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.24  | Alcohol Use Disorder | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.25  | Peripheral Vascular Disease SCT | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.26  | Peripheral Vascular Disease ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.27  | Peripheral Vascular Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.28  | Hepatitis C Condition SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.30  | Hepatitis C Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.31  | Diabetic Neuropathy SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.32  | Diabetic Neuropathy ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.33  | Diabetic Neuropathy Conditions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.35  | Obesity ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.36  | Obesity Conditions | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.37  | Obesity SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.4  | Chronic Kidney Disease Type or Cause SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.41  | Tuberculosis (Disorders) SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.417  | Prediabetes (Borderline Diabetes) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.418  | Prediabetes (Borderline Diabetes) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.419  | Prediabetes (Borderline Diabetes) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.420  | Maturity Onset Diabetes of the Young (MODY) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.43  | Tuberculosis Disorders | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.44  | Tuberculosis (Disorders) Ext | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.45  | Hypoalbuminemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.450  | CKD Progression Risk | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.46  | Hypoalbuminemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.47  | Hypoalbuminemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.48  | Hyperkalemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.480  | Diabetic Coma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.481  | Diabetic Coma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.482  | Diabetic Coma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.49  | Hyperkalemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.490  | Diabetic Peripheral Angiopathy | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.491  | Diabetic Peripheral Angiopathy | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.492  | Diabetic Peripheral Angiopathy | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.496  | Cataract of the Eye | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.497  | Cataract of the Eye | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.498  | Cataract of the Eye | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.499  | Rubeosis Iridis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.5  | Chronic Kidney Disease Type or Cause ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.50  | Hyperkalemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.500  | Rubeosis Iridis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.501  | Rubeosis Iridis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.502  | Rubeosis Iridis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.506  | Emotional Distress caused by Chronic Condition | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.507  | Emotional Distress caused by Chronic Condition | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.508  | Emotional Distress caused by Chronic Condition | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.51  | Anemia Conditions SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.510  | Hypoglycemic Event | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.512  | Hypoglycemic Event | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.513  | Hypoglycemic Event | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.514  | Hypoglycemia Unawareness | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.515  | Hyperglycemic Hyperosmolar Nonketotic Syndrome HHNS | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.516  | Hyperglycemic Hyperosmolar Nonketotic Syndrome HHNS | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.517  | Hyperglycemic Hyperosmolar Nonketotic Syndrome HHNS | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.518  | Ketoacidosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.519  | Ketoacidosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.52  | Anemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.520  | Ketoacidosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.521  | Diabetic Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.522  | Diabetic Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.523  | Diabetic Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.524  | Diabetic Foot Ulcer | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.525  | Diabetic Foot Ulcer | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.526  | Diabetic Foot Ulcer | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.529  | Charcot Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.53  | Anemia Conditions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.530  | Charcot Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.531  | Charcot Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.533  | Cellulitis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.535  | Diabetic Hand or Diabetic Cheiroarthropathy | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.538  | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.539  | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.540  | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.541  | Gangrene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.542  | Gangrene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.543  | Gangrene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.544  | Dupuytren's Contracture | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.545  | Dupuytren's Contracture | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.546  | Dupuytren's Contracture | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.547  | Scleroderma or Thick Skin Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.548  | Scleroderma or Thick Skin Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.549  | Scleroderma or Thick Skin Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.554  | Acanthosis Nigricans | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.555  | Acanthosis Nigricans | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.556  | Acanthosis Nigricans | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.557  | Eruptive Xanthomatosis | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.558  | Periodontitis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.559  | Periodontitis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.560  | Periodontitis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.561  | Amputated Limb (Not Traumatic) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.562  | Amputated Limb (Not Traumatic) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.563  | Amputated Limb (Not Traumatic) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.564  | Hypertension, Essential or Primary ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.565  | Hypertension, Essential or Primary SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.567  | Hypertension, Secondary ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.568  | Hypertension, Secondary SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.571  | Hypertension Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.579  | Cardiomyopathy | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.58  | Hypercalcemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.580  | NYHA Heart Failure Functional Classifications | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.581  | American Heart Association Heart Failure Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.582  | Framingham Risk Assessments | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.583  | American College of Cardiology or American Heart Association Ascvd Risk Score (acc/aha Ascvd Risk) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.584  | Atherosclerotic Cardiovascular Disease | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.586  | Gout | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.587  | Psoriatic Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.588  | Reactive Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.59  | Hypercalcemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.590  | Experience of Traumatic Events | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.591  | Cannabis Use | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.592  | Hearing Impairment | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.6  | Chronic Kidney Disease Type or Cause | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.60  | Hypercalcemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.606  | Angina | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.607  | Angina | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.608  | Angina | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.609  | Unstable Angina | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.61  | Hypocalcemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.610  | Unstable Angina | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.611  | Unstable Angina | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.613  | Ischemic Heart Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.614  | Ischemic Heart Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.615  | Left Ventricular Hypertrophy SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.616  | Stroke History | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.618  | Stroke | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.619  | Transient Ischemic Attack | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.62  | Hypocalcemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.620  | Transient Ischemic Attack | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.621  | Transient Ischemic Attack | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.625  | Aneurysm | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.626  | Aneurysm | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.627  | Aneurysm | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.63  | Hypocalcemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.634  | Aortic Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.635  | Aortic Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.636  | Aortic Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.637  | Carotid Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.638  | Carotid Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.639  | Carotid Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.64  | Hyperphosphatemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.640  | Intracranial Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.641  | Intracranial Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.642  | Intracranial Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.643  | Pulmonary Edema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.644  | Pulmonary Edema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.645  | Pulmonary Edema | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.646  | Osteoarthritis (Oa) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.647  | Osteoarthritis (Oa) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.648  | Osteoarthritis (Oa) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.649  | Rheumatoid Arthritis (Ra) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.65  | Hyperphosphatemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.650  | Rheumatoid Arthritis (Ra) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.651  | Rheumatoid Arthritis (Ra) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.652  | Infectious Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.653  | Infectious Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.654  | Infectious Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.656  | Temporomandibular Disorder Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.658  | Irritable Bowel Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.659  | Irritable Bowel Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.66  | Hyperphosphatemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.660  | Irritable Bowel Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.661  | Neuropathic Pain (Neuralgia) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.662  | Neuropathic Pain (Neuralgia) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.663  | Neuropathic Pain (Neuralgia) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.664  | Neuromas | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.665  | Neuromas | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.666  | Neuromas | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.667  | Phantom Pain | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.668  | Phantom Pain | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.669  | Phantom Pain | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.67  | Hematuria Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.670  | Entrapment Neuropathy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.671  | Entrapment Neuropathy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.672  | Entrapment Neuropathy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.673  | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.674  | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.675  | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.676  | Psychotic Depression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.677  | Psychotic Depression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.678  | Psychotic Depression | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.679  | Post Partum Depression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.68  | Hematuria Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.680  | Post Partum Depression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.681  | Post Partum Depression | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.682  | Seasonal Affective Disorder | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.683  | Seasonal Affective Disorder | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.684  | Seasonal Affective Disorder | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.685  | Psychological Trauma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.686  | Psychological Trauma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.687  | Psychological Trauma | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.688  | Grief or Loss | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.689  | Grief or Loss | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.69  | Hematuria Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.690  | Grief or Loss | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.691  | Suicide Risk | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.692  | Suicide Risk | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.693  | Suicide Risk | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.694  | Vaping | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.695  | Vaping | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.696  | Vaping | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.697  | Tobacco Use or Exposure | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.699  | Tobacco Use or Exposure | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.70  | Metabolic Acidosis Conditions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.701  | Binge Drinking | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.702  | Binge Drinking | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.703  | Binge Drinking | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.704  | Drug Misuse | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.705  | Drug Misuse | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.706  | Drug Misuse | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.707  | Drug Misuse | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.708  | Sensory Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.709  | Sensory Status | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.71  | Metabolic Acidosis Conditions ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.711  | Fall Risk | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.713  | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.714  | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.715  | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.716  | Urinary Incontinence | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.717  | Urinary Incontinence | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.718  | Urinary Incontinence | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.719  | Urinary Urgency | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.72  | Metabolic Acidosis Conditions SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.720  | Urinary Urgency | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.721  | Urinary Urgency | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.722  | Urinary Frequency | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.723  | Urinary Frequency | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.724  | Urinary Frequency | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.725  | Nocturia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.726  | Nocturia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.727  | Nocturia | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.728  | Pelvic Organ Prolapse | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.729  | Pelvic Organ Prolapse | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.73  | Hyperlipidemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.730  | Pelvic Organ Prolapse | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.731  | Erectile Dysfunction | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.732  | Erectile Dysfunction | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.733  | Erectile Dysfunction | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.734  | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.735  | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.736  | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.737  | Recurrent Urinary Tract Infections | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.738  | Recurrent Urinary Tract Infections | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.739  | Recurrent Urinary Tract Infections | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.74  | Hyperlipidemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.740  | Hypertriglyceridemia | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.741  | Hypertriglyceridemia | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.742  | Hypertriglyceridemia | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.743  | Hypothyroidism | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.744  | Hypothyroidism | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.745  | Hypothyroidism | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.746  | Menopause | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.747  | Menopause | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.748  | Menopause | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.749  | Testicular Hypofunction | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.75  | Hyperlipidemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.750  | Testicular Hypofunction | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.751  | Testicular Hypofunction | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.752  | Primary Aldosteronism | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.753  | Primary Aldosteronism | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.754  | Primary Aldosteronism | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.755  | Restless Leg Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.756  | Restless Leg Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.757  | Restless Leg Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.759  | Claudication | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.76  | Chronic Pain Conditions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.760  | Claudication | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.761  | Claudication | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.762  | Angioedema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.763  | Angioedema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.764  | Angioedema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.768  | Nonalcoholic Fatty Liver Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.769  | Nonalcoholic Fatty Liver Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.77  | Chronic Pain ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.770  | Nonalcoholic Fatty Liver Disease | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.771  | Thalassemia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.772  | Thalassemia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.773  | Thalassemia | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.78  | Chronic Pain SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.79  | Arthritis Disorders SCT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.790  | Urine Protein to Creatinine Ratio (UPCR) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.791  | 24 Hour Urine Volume | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.792  | 24 Hour Urine Protein Excretion | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.793  | Total Carbon Dioxide or Bicarbonate in blood, serum or plasma | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.794  | Calcium (Not Corrected for Serum Albumin) in Blood, Plasms, or Serum | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.795  | B Type Natriuretic Peptide [Bnp] in Blood, Serum or Plasma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.797  | N Terminal Pro_B_Type Natriuretic Peptide [Nt_Probnp] in blood, serum or plasma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.799  | Temporomandibular Disorder Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.80  | Arthritis Disorders ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.800  | Temporomandibular Disorder Diagnosis | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.801  | High Sensitivity Troponin | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.804  | Aspartate Transaminase or Alanine Aminotransferase Ratio | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.805  | Alkaline Phosphatase (Alp) in Blood, Serum or Plasma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.806  | Gamma Glutamyl Transpeptidase (Ggt) in blood, serum or plasma | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.807  | Triiodothyronine in serum or plasma | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.808  | Fasting Blood Glucose | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.809  | Random Blood Glucose Test | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.81  | Arthritis Disorders | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.810  | Uric Acid (Urate) in blood, serum or plasma | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.811  | Aldosterone/Renin Ratio | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.812  | Serum Rheumatoid Factor | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.813  | Blood Ethanol Level | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.814  | Drugs of Abuse Screen in Hair | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.815  | Drugs of Abuse Screen in Urine | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.816  | Drugs of Abuse Screen in Blood | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.817  | Drugs of Abuse Screen in Tissue | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.818  | Drugs of Abuse Screen in Body Fluid | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.819  | Urea Reduction Ratio | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.82  | Preeclampsia Disorders SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.822  | Bowel Sounds | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.823  | Uroflowmetry | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.826  | Gait Quality | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.828  | Balance Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.83  | Preeclampsia Disorders ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.836  | Sit to Stand Ability | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.84  | Preeclampsia Disorders | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.840  | Spinal Cord Compression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.841  | Spinal Cord Compression | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.842  | Alcohol Use (Revised 2021) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.843  | Alcohol Use (Revised 2021) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.844  | Alcohol Use (Revised 2021) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.845  | Alcohol Use | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.85  | Hyperuricemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.86  | Hyperuricemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.864  | Kidney Biopsy Report | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.867  | Skin Biopsy Report | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.868  | Muscle Biopsy Report | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.869  | Gastric Tissue Biopsy Report | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.87  | Hyperuricemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.870  | Bone Biopsy Report | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.873  | Echocardiogram | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.88  | Vitamin D Deficiency Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.880  | Spinal or Back CT | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.881  | Chest CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.882  | Abdominal or Pelvic CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.883  | Limb CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.884  | Heart Calcium Score | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.885  | Coronary CT Angiogram | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.886  | Limb CT Angiogram | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.888  | Chest CT Angiogram | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.889  | Head and Neck CT Angiogram | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.89  | Vitamin D Deficiency Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.891  | Gastrointestinal Tract X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.892  | Gallbladder X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.893  | Kidney X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.894  | Abdomen X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.895  | Pelvis X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.896  | Hand X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.897  | Wrist X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.898  | Forearm X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.899  | Elbow X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.90  | Vitamin D Deficiency Conditions | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.900  | Upper Arm X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.901  | Shoulder X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.902  | Upper Extremity X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.903  | Foot X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.904  | Ankle X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.905  | Shin X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.906  | Knee X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.907  | Thigh X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.908  | Hip X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.909  | Lower Extremity X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.91  | Alkaline Phosphatase Deficiency Conditions SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.910  | Abdominal MRI | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.911  | Adrenal Gland MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.912  | Kidney MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.913  | Pancreas MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.915  | Kidney MRA | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.916  | Chest Region MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.917  | Pulmonary MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.918  | Cardiac MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.92  | Alkaline Phosphatase Deficiency Conditions ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.920  | Spine MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.921  | Head and Neck MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.922  | Brain MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.923  | Pelvic Region MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.924  | Knee MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.925  | Foot MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.927  | Shoulder MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.928  | Lower Extremity MRA | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.93  | Alkaline Phosphatase Deficiency Conditions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.930  | Spine X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.933  | Hip MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.934  | Thigh or Femur MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.935  | Ankle MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.936  | Lower Extremity MRI | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.937  | Forearm MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.938  | Elbow MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.939  | Wrist MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.94  | Uremic Pruritus Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.940  | Hand MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.942  | Upper Extremity MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.943  | Abdominal MRA | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.944  | Chest MRA | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.945  | Upper Extremity MRA | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.947  | Head and Neck MRA | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.948  | Pelvic Region MRA | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.949  | Functional MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.95  | Uremic Pruritus Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.951  | Optical Coherence Tomography | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.954  | Bathing or grooming/hygiene (ADL/IADL) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.955  | Dressing (ADL or IADL) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.956  | Toileting (ADL or IADL) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.957  | Transferring (ADL or IADL) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.958  | Walking or ambulation/locomotion (ADL/IADL) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.96  | Uremic Pruritus Conditions | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.960  | Domestic Duties or Household Tasks (ADL/IADL) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.961  | Telephone Use (ADL or IADL) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.962  | Bed Mobility (ADL or IADL) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.963  | Stair Use (ADL or IADL) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.964  | Medication Management (ADL or IADL) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.967  | Electromyography | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.968  | Electroencephalogram | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.969  | Exercise Stress Test | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.97  | Insomnia Disorders | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.976  | Sleep Duration, Device | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.977  | Steps Per Time, Device | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.978  | Physical Activity Level, Device | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.979  | Cognitive Function Clinician Interpretation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.98  | Insomnia Disorders ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.987  | Psychosis | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.99  | Insomnia Disorders SCT | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.991  | Suicidal Ideation and Behaviors | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.994  | Sleep Duration | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.996  | Pain Intensity or Severity | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.997  | Pain Quality | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.4  | Glaucoma ICD10 | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.5  | Glaucoma SNOMED | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.1  | Scleritis | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.2  | Scleritis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.3  | Scleritis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.1  | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.2  | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Non Diagnostic or Non CT | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.3  | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Nuclear Medicine With CT | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.4  | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography CT Without Specified Body Region | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.6  | Outpatient Encounter Locations | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.7  | Outpatient Activity Codes | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.6  | Anaphylaxis, ICD10CM codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.60  | Guillain Barre Syndrome, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.61  | Febrile seizure, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.62  | Encephalomyelitis and encephalitis, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.63  | Disseminated Intravascular Coagulation, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.64  | Deep Vein Thrombosis, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.65  | Bells Palsy, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.66  | Appendicitis, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.67  | Anaphylaxis, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.68  | Acute Myocardial Infarction, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.69  | Multisystem Inflammatory Syndrome, SNOMED codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.7  | Anaphylaxis, SNOMED codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.70  | Multisystem Inflammatory Syndrome, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.71  | Transfusion CPT codes for exposure identification | active | 2021-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.72  | Transfusion ICD9 codes for exposure identification | active | 2021-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.73  | Transfusion ICD10PCS codes for exposure identification | active | 2021-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.74  | Transfusion CPT, ICD9, ICD10PCS codes for exposure identification | active | 2021-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75  | COVID19 vaccine ICD10PCS codes for exposure identification | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.8  | Appendicitis, SNOMED codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.9  | Appendicitis, ICD10CM codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.1  | Test Diabetes codes | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.100  | Cardiomyopathy Hypertrophic Condition | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.12  | Metabolic Syndrome LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.15  | MetabolicSyndromeCondition | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.16  | Annual Physical ICD9 CN5 | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.164  | Diabetic Retinal Screening HD CPT for Tax Pair | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.165  | Optometrist and Ophthalmologist Taxonomy HD Taxonomy | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.167  | End Stage Renal Disease (ESRD)_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.168  | End Stage Renal Disease (ESRD)_HD_ICD9 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.169  | End Stage Renal Disease (ESRD)_HD_ICD10 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.17  | Annual Physical ICD10 CN5 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.170  | End Stage Renal Disease (ESRD)_HD_HCPCS | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.171  | End Stage Renal Disease (ESRD)_HD_LOINC | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.172  | End Stage Renal Disease (ESRD)_HD_Clinical Condition Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.173  | Systolic Blood Pressure_HD_SNOMED | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.174  | Systolic Blood Pressure_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.175  | Systolic Blood Pressure_HD_LOINC | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.176  | Systolic Blood Pressure_HD | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.177  | Diastolic Blood Pressure_HD_SNOMED | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.178  | Diastolic Blood Pressure_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.179  | Diastolic Blood Pressure_HD_LOINC | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.18  | Annual Physical SNOMED CN5 | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.180  | Diastolic Blood Pressure_HD | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.181  | Remote Blood Pressure_HD_SNOMED | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.182  | Remote Blood Pressure_HD | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.183  | Remote Blood Pressure_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.641  | b.well Adult Tetanus Vaccine CN_CVX | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.642  | b.well Adult Tetanus Vaccine CN_Exclusions_SNOMED | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.643  | b.well Adult Tetanus Vaccine CN_Exclusions | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.644  | BWellAdultTetanusVaccineCN_RxNorm | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.645  | Pneumococcal Vaccine HD_CN_ Allergy | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.646  | bwell COVID Vaccine CN_Allergy | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.647  | bwell Covid Vaccine CN_Allergy_SNOMED | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.648  | bwell COVID Vaccine CN_Met | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.9  | Metabolic Syndrome ICD10 | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.91  | Cardiomyopathy Dilated ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.92  | Cardiomyopathy Dilated ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.93  | Cardiomyopathy Dilated SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.94  | Cardiomyopathy Dilated Condition | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.95  | Cardiomyopathy Dilated LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.96  | Cardiomyopathy Hypertrophic ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.97  | Cardiomyopathy Hypertrophic ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.98  | Cardiomyopathy Hypertrophic SNOMED | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.99  | Cardiomyopathy Hypertrophic LOINC | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.12  | SNOMEDFindingValuesQualifierValue | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.13  | SNOMED Organism from LOINC Answer List | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.18  | Medication Prescribable Brand Name | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.2  | SNOMED Organisms | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.22  | Medicinal Ingredients RXNORM | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.1  | Mental Status Observation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.10  | Other Unknown Nulls | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.11  | Sexual Orientation Including nulls and Data Absent Reason | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.12  | Pregnancy Status Observation | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.2  | No Healthcare Agent Included Reason | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.3  | Sex | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.4  | Asked Declined Data Absent Reason | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.5  | Act Encounter Codes | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.6  | Completed or Nullified Act Status | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.7  | Data Absent Reason Types of Unknown | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.8  | Medication Adherence | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.2  | Sickle Cell Disease | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.4  | Depression | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.1  | Food Insecurity Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.100  | Intimate Partner Violence Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.101  | Less Than High School Education Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.102  | Less Than High School Education Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.103  | Less Than High School Education Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.106  | Transportation Insecurity Interventions SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.107  | Financial Insecurity Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.108  | Financial Insecurity Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.109  | Financial Insecurity Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.11  | Food Insecurity Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.110  | Medical Cost Burden Goals SNOMED CT | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.111  | Health Insurance Coverage Status Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.112  | Health Literacy Diagnoses SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.113  | Health Literacy Diagnoses ICD10CM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.114  | Health Literacy Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.115  | Health Literacy Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.116  | Health Literacy Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.117  | Health Literacy Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.118  | Health Literacy Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.119  | Health Literacy Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.120  | Medical Cost Burden Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.121  | Health Insurance Coverage Status Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.122  | Medical Cost Burden Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.123  | Medical Cost Burden Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.124  | Health Insurance Coverage Status Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.125  | Health Insurance Coverage Status Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.126  | Social Determinants of Health Screening Assessments | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.127  | Food Insecurity Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.128  | Transportation Insecurity Screening Assessments | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.129  | Homelessness Screening Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.13  | Homelessness Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.130  | Housing Instability Screening Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.131  | Inadequate Housing Screening Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.132  | Less Than High School Education Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.133  | Unemployment Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.134  | Veteran Status Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.135  | Social Connection Screening Assessments | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.136  | Stress Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.137  | Cognitive disorder Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.138  | Financial Insecurity Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.139  | Material Hardship Screening Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.14  | Homelessness Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.140  | Intimate Partner Violence Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.141  | Health Literacy Screening Assessments | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.142  | Medical Cost Burden Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.143  | Health Insurance Coverage Status Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.144  | Elder Abuse Screening Assessments | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.145  | Less Than High School Education Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.146  | Financial Insecurity Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.147  | Health Insurance Coverage Status Diagnoses ICD10CM | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.148  | Health Insurance Coverage Status Diagnoses | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.149  | Health Insurance Coverage Status Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.15  | Food Insecurity Interventions CPT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.150  | Material Hardship Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.151  | Medical Cost Burden Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.152  | Medical Cost Burden Diagnoses SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.153  | Medical Cost Burden Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.154  | Medical Cost Burden Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.157  | Transportation Insecurity Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.158  | Homelessness Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.159  | Homelessness Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.16  | Food Insecurity Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.160  | Housing Instability Goals SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.161  | Housing Instability Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.162  | Transportation Insecurity Goals SNOMED CT | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.163  | Transportation Insecurity Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.164  | Veteran Status Interventions SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.167  | Inadequate Housing Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.168  | Material Hardship Screening Assessments Questions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.169  | Stress Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.17  | Food Insecurity Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.170  | Transportation Insecurity Screening Assessments Questions | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.171  | Unemployment Screening Assessments Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.172  | Veteran Status Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.173  | Financial Insecurity Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.174  | Food Insecurity Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.175  | Health Literacy Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.176  | Homelessness Screening Assessments Answers | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.177  | Housing Instability Screening Assessments Answers | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.178  | Inadequate Housing Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.179  | Less Than High School Education Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.18  | Homelessness Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.180  | Material Hardship Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.181  | Stress Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.182  | Transportation Insecurity Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.183  | Unemployment Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.184  | Veteran Status Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.185  | Health Insurance Coverage Status Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.186  | Health Insurance Coverage Status Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.187  | Medical Cost Burden Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.188  | Medical Cost Burden Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.189  | Elder Abuse Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.19  | Homelessness Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.190  | Elder Abuse Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.191  | Elder Abuse Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.192  | Veteran Status Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.193  | Financial Insecurity Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.194  | Food Insecurity Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.195  | Health Literacy Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.196  | Homelessness Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.197  | Housing Instability Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.198  | Intimate Partner Violence Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.199  | Less Than High School Education Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.20  | Homelessness Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.200  | Material Hardship Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.201  | Medical Cost Burden Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.202  | Social Connection Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.203  | Stress Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.204  | Transportation Insecurity Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.205  | Unemployment Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.206  | Social Determinants of Health Screening Assessments And Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.207  | Social Determinants of Health Screening Assessments Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.208  | Social Determinants of Health Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.209  | Intimate Partner Violence Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.21  | Homelessness Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.210  | Social Connection Screening Assessments Answers | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.211  | Intimate Partner Violence Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.212  | Social Connection Screening Assessments Questions | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.213  | Health Insurance Coverage Status Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.214  | Veteran Status Goals | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.215  | Veteran Status Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.217  | Digital Literacy Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.218  | Digital Literacy Diagnoses ICD10CM | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.219  | Digital Literacy Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.22  | Housing Instability Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.220  | Digital Literacy Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.224  | Digital Literacy Diagnoses | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.225  | Digital Literacy Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.226  | Digital Literacy Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.227  | Digital Literacy Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.229  | Digital Access Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.23  | Housing Instability Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.230  | Digital Access Diagnoses ICD10CM | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.231  | Digital Access Diagnoses | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.232  | Digital Access Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.233  | Digital Access Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.234  | Digital Access Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.235  | Digital Access Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.236  | Digital Access Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.237  | Digital Access Screening Assessments | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.238  | Digital Access Screening Assessments Questions | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.239  | Digital Access Screening Assessments Answers | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.24  | Housing Instability Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.240  | Digital Access Screening Assessments And Questions | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.241  | Utility Insecurity Diagnoses SNOMED CT | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.242  | Utility Insecurity Diagnoses ICD10CM | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.243  | Utility Insecurity Diagnoses | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.244  | Utility Insecurity Goals SNOMED CT | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.245  | Utility Insecurity Goals | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.246  | Utility Insecurity Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.247  | Utility Insecurity Procedures | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.248  | Utility Insecurity Screening Assessments | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.249  | Utility Insecurity Screening Assessments Questions | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.25  | Transportation Insecurity Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.250  | Utility Insecurity Screening Assessments Answers | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.251  | Utility Insecurity Screening Assessments And Questions | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.252  | Utility Insecurity Service Requests | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.253  | Social Determinants of Health General Interventions HCPCS | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.254  | Incarceration Status Diagnoses ICD10CM | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.255  | Incarceration Status Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.256  | Incarceration Status Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.257  | Incarceration Status Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.258  | Incarceration Status Diagnoses | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.259  | Incarceration Status Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.26  | Transportation Insecurity Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.260  | Incarceration Status Procedures | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.261  | Incarceration Status Service Requests | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.262  | Language Access Diagnoses | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.263  | Language Access Diagnoses ICD10CM | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.264  | Language Access Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.265  | Language Access Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.266  | Language Access Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.267  | Language Access Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.268  | Language Access Procedures | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.269  | Language Access Service Requests | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.27  | Transportation Insecurity Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.270  | Language Access Screening Assessments | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.271  | Language Access Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.272  | Language Access Screening Assessments Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.273  | Language Access Screening Assessments And Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.28  | Transportation Insecurity Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.29  | Financial Insecurity Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.3  | Food Insecurity Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.30  | Financial Insecurity Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.31  | Financial Insecurity Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.32  | Financial Insecurity Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.33  | Material Hardship Diagnoses ICD10CM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.34  | Material Hardship Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.35  | Material Hardship Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.36  | Material Hardship Goals SNOMED CT | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.37  | Material Hardship Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.38  | Material Hardship Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.39  | Material Hardship Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.4  | Food Insecurity Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.40  | Unemployment Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.41  | Unemployment Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.42  | Unemployment Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.43  | Housing Instability Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.44  | Housing Instability Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.45  | Housing Instability Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.46  | Inadequate Housing Diagnoses SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.47  | Inadequate Housing Diagnoses ICD10CM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.48  | Inadequate Housing Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.49  | Inadequate Housing Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.5  | Social Determinants of Health General Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.50  | Inadequate Housing Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.51  | Inadequate Housing Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.52  | Inadequate Housing Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.53  | Inadequate Housing Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.54  | Less Than High School Education Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.55  | Less Than High School Education Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.56  | Less Than High School Education Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.57  | Less Than High School Education Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.58  | Unemployment Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.59  | Unemployment Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.6  | Food Insecurity Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.60  | Unemployment Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.61  | Elder Abuse Diagnoses ICD10CM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.62  | Elder Abuse Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.63  | Elder Abuse Diagnoses | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.64  | Elder Abuse Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.65  | Elder Abuse Goals | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.66  | Elder Abuse Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.67  | Elder Abuse Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.68  | Elder Abuse Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.69  | Unemployment Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.7  | Food Insecurity Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.70  | Unemployment Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.71  | Social Determinants of Health Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.72  | Stress Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.73  | Stress Interventions SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.74  | Stress Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.75  | Stress Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.76  | Veteran Status Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.77  | Veteran Status Diagnoses ICD10CM | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.78  | Veteran Status Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.79  | Social Connection Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.8  | Social Determinants of Health General Interventions CPT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.80  | Social Connection Diagnoses ICD10CM | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.81  | Social Connection Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.82  | Intimate Partner Violence Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.83  | Intimate Partner Violence Diagnoses ICD10CM | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.84  | Intimate Partner Violence Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.85  | Stress Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.86  | Stress Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.87  | Stress Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.88  | Social Connection Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.89  | Social Connection Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.9  | Food Insecurity Interventions HCPCS | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.90  | Veteran Status Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.91  | Veteran Status Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.92  | Stress Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.93  | Social Connection Interventions SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.94  | Social Connection Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.95  | Social Connection Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.96  | Intimate Partner Violence Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.97  | Intimate Partner Violence Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.98  | Intimate Partner Violence Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.99  | Intimate Partner Violence Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.105  | Mechanical Ventilation Procedures | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.106  | Mechanical Ventilation | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.107  | Mechanical Ventilation | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.109  | aPTT Tests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119  | Opioid Antagonist | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.12  | High Risk Diagnosis for AKI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.120  | Opioids | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.124  | Immune Modulators | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.130  | Suicide Attempt | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.134  | Central Nervous System Depressants | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.136  | Leukemia or Lymphoma | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.137  | Liver Disease Moderate to Severe | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.138  | COVID19 | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.139  | COVID 19 | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.14  | Hemolytic Uremic Syndrome (HUS) | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.140  | COVID 19 | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.162  | Obesity | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.163  | Antidepressants | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.164  | Antihypertensives | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.165  | Delirium | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.166  | Dementia | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.167  | Psychosis | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.168  | Delirium or Dementia and Other Psychoses | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.169  | Depression | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.170  | Diuretics | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.171  | Epilepsy | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.172  | Neurologic Movement Disorders | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.173  | Neurologic Disorders, Other | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.174  | Neurologic Movement and Related Disorders | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.175  | Peripheral Neuropathy | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.176  | Stroke | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.177  | Abnormal Weight Loss and Malnutrition | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.178  | Intubation | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.179  | Intubation | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.180  | Tracheostomy Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.181  | Tracheostomy Procedures | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.182  | Head and Neck Surgeries with High Risk Airway Compromise | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.185  | Spinal Surgery | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.187  | Routes of Administration for Opioid Antagonists | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.19  | High Risk Procedures for AKI | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.197  | Hospital Based Dialysis Services | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.198  | Hospital Based Dialysis Services | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.199  | Hospital Based Dialysis Services | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.200  | Nephrectomy | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.201  | Thrombotic Thrombocytopenic Purpura | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.204  | VTE Prophylaxis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.205  | Moderate Injuries | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.206  | General and Neuraxial Anesthesia | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.207  | General and Neuraxial Anesthesia | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.208  | General and Neuraxial Anesthesia | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.209  | Non Invasive Oxygen Therapy by Nasal Cannula or Mask | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.21  | Creatinine Mass Per Volume | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.210  | Continuous and Bilevel Positive Airway Pressure | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.211  | Continuous and Bilevel Positive Airway Pressure | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.213  | Non Invasive Oxygen Therapy | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.214  | Non Invasive Oxygen Therapy Devices | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.216  | Procedural Hospital Locations | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.217  | ASA physical status class | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.218  | Blood urea nitrogen lab test | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.219  | Hemoglobin lab test | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.22  | Anticoagulants for All Indications | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.220  | Smoking status | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.221  | Albumin lab test | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.222  | Leukocyte count lab test | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.223  | Bilirubin lab test | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.224  | Aspartate transaminase lab test | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.226  | Cardiac Arrest | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.23  | Coagulation Disorders | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.230  | PO Antibacterials | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.231  | Injectable Antifungals | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.238  | Neuromuscular Disorder | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.239  | Neuromuscular Disorder | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.24  | Malignant Bone Disease | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.240  | Degenerative Neurological Disorder | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.241  | Degenerative Neurological Disorder | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.242  | Heart and Lung Transplants | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.243  | Heart and Lung Transplants | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.245  | Lung Resections and Excisions | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.246  | Lung Resections and Excisions | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.247  | Chest Wall Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.248  | Chest Wall Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.249  | Maxillary Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.250  | Maxillary Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.251  | Head, Neck, and Thoracic Surgeries with High Risk Airway Compromise | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.252  | Anesthesia Requiring Monitored Care | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.253  | Anesthesia Requiring Monitored Care | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.255  | Anesthesia Requiring Monitored Care | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.256  | Osteoporosis | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.260  | Rivaroxaban Anticoagulant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.262  | Fondaparinux Anticoagulant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.263  | Dalteparin Anticoagulant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.264  | Heparin | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.268  | Enoxaparin Anticoagulant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.271  | Undetectable Lab Result Value | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.272  | Undetectable Lab Result Value | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.274  | Dietary Recommendations | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.275  | Bariatric Procedures | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.276  | Telemedicine Services | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.277  | Prostate Cancer Treatment | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.28  | Traumatic Avulsion of Kidney | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.29  | Rapidly Progressive Nephritic Syndrome | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.301  | LDL Cholesterol | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.33  | Obstetrics and VTE Obstetrics | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34  | Glucose Lab Test Mass Per Volume | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.349  | Tuberculosis for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.350  | Tuberculosis for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351  | Tuberculosis for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.352  | Androgen Deprivation Therapy for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353  | Bacillus Calmette Guerin for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354  | Bladder Cancer for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.355  | Chemotherapy Agents for Advanced Cancer | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.356  | Cystectomy for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.357  | Cystectomy for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.358  | Cystectomy for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359  | DEXA Bone Density for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.360  | Hospital Services for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.361  | Immunocompromised Conditions | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.362  | Immunocompromised Conditions | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363  | Immunocompromised Conditions | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.364  | Immunosuppressive Drugs for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365  | Mixed Histology Urothelial Cell Carcinoma for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.366  | Morbid Obesity | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.367  | Morbid Obesity | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.368  | Morbid Obesity | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.369  | Unavailability of Bacillus Calmette Guerin for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.370  | Urinary Retention | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.371  | Urinary Retention | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.372  | Urinary Retention | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.374  | Face to Face Interaction | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.375  | Face to Face Interaction | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.376  | HIV Viral Load Tests | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.377  | HIV Viral Load Tests | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.389  | Syphilis Tests | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.4  | Nephrectomy | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.79  | Acute Brain or Spinal Injury or Hemorrhage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.8  | Large Body Surface Area (BSA) Burns | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.80  | Pulmonary Arterial Thrombectomy | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.81  | Extracorporeal Membrane Oxygenation | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.85  | Elective Inpatient Encounter | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.86  | Intubation | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.88  | Acute Respiratory Failure | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.89  | Tracheostomy Diagnoses | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.90  | Tracheostomy Procedures | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.91  | Neuromuscular Disorder | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.92  | Degenerative Neurological Disorder | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.93  | Head and Neck Surgeries with High Risk Airway Compromise | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.94  | Oxygen Partial Pressure in Arterial Blood | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.95  | Carbon Dioxide Partial Pressure in Arterial Blood | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.96  | Arterial Blood pH | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.2  | Psychological Neuropsychological or Neurobehavioral Testing | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.3  | Psychological or Neuropsychological Testing | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.10  | Tricuspid Valve Regurgitation | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.12  | Hypertension | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.2  | Valvular Heart Disease | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.22  | Acute Kidney Injury | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.23  | Anemia | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.24  | Cardiac Arrhythmias | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.25  | Attention Deficit and Hyperactivity Disorder | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.26  | Cerebrovascular Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.27  | Seizure Disorder | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.28  | Proteinuria | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.29  | Thyroid Hormone Disorder | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.30  | Thromboembolic Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.31  | Parkinson's Disease and Parkinsonism | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.32  | Upper GI Diseases | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.33  | Failure to Thrive | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.34  | Osteoporosis | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.35  | Mood Disorders | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.36  | Dyslipidemia | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.37  | Heart Failure | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.38  | Coronary Artery Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.39  | Chronic Kidney Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.40  | Chronic Obstructive Pulmonary Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.41  | Diabetes Mellitus | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.1  | EventTiming-TimingEvent | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.2  | EventTiming-EventTiming | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.1  | Gonorrhea Screening | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.2  | Abnormal Weight Loss | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.2  | Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.3  | Prescribable brand and generic insulins and analogues | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.4  | eGFR Using 2021 Race Free Formulas | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.5  | Fructosamine in Serum or Plasma | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.6  | Glucose tests in venous blood, capillary blood, serum/plasma for Diabetes | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.7  | Creatinine in serum/plasma | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9  | IgE Agonists, prescribable | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.10  | Estrogen Receptor Testing for Orserdu | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.100  | MMR Proficient | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.101  | Systemic Cancer Directed Therapy | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.102  | Face To Face Interaction | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.104  | Erdafitinib | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.107  | Chemotherapy Encounter | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.108  | Urothelial Cancers ICD9 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.109  | Urothelial Cancer ICD10 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.11  | Estrogen Receptor Test for Orserdu | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.110  | Urothelial Cancers | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.111  | Prior Therapies for Erdafitinib | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.112  | Urothelial Cancer Histologies | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.113  | Malignant Tumor Behavior | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.114  | Localized Bladder Cancer Stage SNOMED | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.116  | Localized Bladder Cancer Staging | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.117  | Advanced Bladder Cancer Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.118  | Localized Bladder Cancer T Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.119  | Localized Bladder Cancer T Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.12  | Negative | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.120  | Localized Bladder Cancer N Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.121  | Localized Bladder Cancer M Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.122  | Advanced Bladder Cancer M Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.124  | Locoregional Urothelial Cancer ICD9 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.125  | Locoregional Urothelial Cancer ICD10 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.126  | Locoregional Urothelial Cancer SNOMED | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.127  | Locoregional Urothelial Cancer | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.128  | FGFR3 Gene | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.129  | FGFR3 Gene Interpretation Positive SNOMED | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.13  | HER2 Negative | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.130  | FGFR3 Gene Interpretation Positive LOINC | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.131  | FGFR3 Gene Interpretation Positive NCI | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.133  | FGFR3 Gene Interpretation Positive | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.134  | FGFR3 Gene Interpretation Negative SNOMED | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.135  | FGFR3 Gene Interpretation Negative NCI | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.137  | FGFR3 Gene Interpretation Negative | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.138  | FGFR3 Molecular Variants | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.139  | Tumor Behavior | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.14  | Endocrine Therapy | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.140  | Physcological Support for Cancer | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.141  | Referral For Pain From Cancer | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.142  | Cancer Pain Education | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.143  | Telehealth Encounters | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.144  | Pain Assessment Score | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.146  | Telehealth Encounters SNOMEDCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.147  | Telehealth Encounters CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.148  | Telehealth Encounters HCPCS | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.149  | Telehealth Encounters All | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.15  | All Metastatic Sites | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.150  | Chemo Admin SNOMEDCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.151  | Chemo Admin CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.152  | Chemo Admin HCPCS | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.153  | Chemotherapy Administration All | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.154  | Radiation Treatment CPT | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.155  | Radiation Treatment HCPCS | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.156  | Radiation Treatment SNOMEDCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.157  | Radiation Treatment All | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.158  | Bipolar Diagnosis Codes | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.159  | Telephone Visits SNOMED | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.16  | All Metastatic Sites | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.160  | Telephone Visit CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.161  | Telephone Visits All | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.162  | Adolescent depression screening assessment | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.163  | Adult depression screening assessment LOINC | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.165  | Referral for Depression Adult | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.166  | Referrals for Adolescent Depression | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.167  | Follow Ups for Adolescent Depression | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.168  | FollowUps for Adult Depression | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.169  | Depression Screen Declined for Medical Reason | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.17  | Metastatic Breast Cancer | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.170  | Physical Therapy Evaluations SNOMEDCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.171  | Physical Therapy Evaluation CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.172  | Physical Therapies Evaluations | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.173  | Non Opioid Analgesics | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.174  | Adjuvant Analgesics | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.176  | Lung Cancer ICD9 | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.177  | Lung Cancer ICD10 | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.178  | Lung Cancer | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.179  | Prior Therapies for Osimertinib | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.18  | Stage IA | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.181  | Plan of Care for Pain | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.182  | All Antineoplastic Agents | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.183  | Locally Advanced NSCLC Stage Group | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.185  | Localized NSCLC Stage Group SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.186  | Radiation Treatment Management | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.187  | Plan of Care | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.188  | Documentation of Plan of Care | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.189  | Pain Present | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.19  | Stage IB | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.190  | Localized NSCLC Stage Group NCIM | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.192  | Localized NSCLC Stage Group | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.193  | Advanced NSCLC Stage Group | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.194  | NSCLC M Stage (metastatic) | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.195  | NSCLC T Stage | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.196  | NSCLC N Stage | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.197  | SCLC and rarer lung cancer histology | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.198  | EGFR Gene | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.199  | EGFR Gene Interpretation Positive SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.20  | Stage IIA | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.200  | EGFR Gene Interpretation Positive LOINC | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.201  | EGFR Gene Interpretation Positive | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.202  | EGFR Osimertinib Molecular Variants | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.203  | EGFR Generic Molecular Variant NCIM | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.204  | EGFR Generic Molecular Variant SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.205  | EGFR Generic Molecular Variant LOINC | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.206  | EGFR Molecular Variants Osimertinib PM | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.207  | Osimertinib | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.208  | Pemetrexed | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.209  | Radiation Treatment Management SNOMEDCT | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.21  | Stage IIB | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.210  | Radiation Treatment Management Codes | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.211  | Radiation Treatment Delivery CPT | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.212  | 77427 Management Code | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.213  | Radiation Treatment Delivery HCPCS | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.214  | Radiation Treatment Delivery NCIM | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.215  | Radiation Treatment Delivery SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.216  | Radiation Treatment Delivery | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.217  | MET Gene Test | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.219  | Tepotinib | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.22  | Stage IIIA | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.220  | MET Positive gene interpretation | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.227  | MET Exon 14 skipping molecular variant | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.23  | Stage IIIB | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.230  | All Cancer Directed therapies | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.231  | EGFR Amivantamab Molecular Variants | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.232  | EGFR Molecular Variants Amivantamab PM | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.233  | test43 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.234  | ROS1 Molecular Variants Repotrectinib PM | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.235  | ROS1 Repotrectinib Molecular Variants | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.236  | ROS1 Negative (geneinterpretation) SNOMEDCT | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.237  | ROS1 Negative (geneinterpretation) NCI | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.238  | ROS1 Negative (geneinterpretation) SNOMEDCT,NCI | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.239  | ROS1 Positive (geneinterpretation) | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.24  | Stage IIIC | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.240  | ROS1 results (HGNC) | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.241  | ROS1 Gene Rearrangement | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.242  | RET Test (HGNC) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.243  | RET Positive (Genei interpretation ) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.244  | RET Gene Rearrangement | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.245  | RET Negative (geneinterpretaion) SNOMED | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.246  | RET Negative (geneinterpretaion) NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.247  | RET Negative (geneinterpretaion) SNOMEDCT,NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.248  | RET Fusion Molecular Variants | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.249  | pralsetinib | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.25  | ESR1 Gene Test | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.250  | Repotrectinib Value set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.251  | Amivantamab | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.252  | Alectinib Drug | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.253  | Gemcitabine Drug Value set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.254  | vinorelbine Drug | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.255  | NSCLC_Tumor_resection SNOMEDCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.256  | NSCLC_Tumor_resection CPT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.257  | NSCLC_Tumor_resection SNOMEDCT CPT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.258  | ALK results (HGNC) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.259  | ALK Positive (geneinterpretation) SNOMED | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.26  | ESR1 Genetic Mutation | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.260  | ALK Positive (geneinterpretation) NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.261  | ALK Positive (geneinterpretation) SNOMEDCT NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.262  | ALK Negative (geneinterpretation) SNOMEDCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.263  | ALK Negative (geneinterpretation) NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.264  | ALK Negative (geneinterpretation) SNOMEDCT NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.265  | Locoregional Sites | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.266  | NSCLC N2 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.267  | NSCLC N1 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.268  | NSCLC N0 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.269  | NSCLC T3_T4 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.27  | Genetic Test Finding | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.270  | NSCLC T2 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.271  | NSCLC T1 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.272  | Locally_Advanced_Metastatic_NSCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.273  | Localized_Inclusion_NSCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.274  | Localized_Exclusion_NSCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.275  | tarlatamab dlle | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.276  | Extensive SCLC Stage Group SNOMEDCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.277  | Extensive SCLC Stage Group NCIM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.278  | Extensive SCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.279  | Localized SCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.28  | Her2 Negative | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.280  | SCLC M Stage (metastatic) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.281  | SCLC T Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.282  | SCLC N Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.283  | SCLC histology (to include those patients) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.284  | Binimetinib | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.285  | Encorafenib | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.286  | Encorafenib PM Molecular variant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.288  | BRAF Positive (geneinterpretation) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.289  | BRAF test (HGNC) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.29  | HER2 Positive | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.292  | Prior therapy for Amivantamab | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.293  | ENHERTU Drug | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.294  | Metastatic_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.295  | Locally_Advanced_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.296  | Localized_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.297  | Solid cancer M Stage (metastatic) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.298  | Solid Cancer T Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.299  | Solid Cancer N Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.30  | HER2 Positive | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.302  | HER2_IHC_Positive | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.303  | HER2 Negative (geneinterpretation/Labtestvalue) SNOMED | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.304  | HER2 Negative (geneinterpretation/Labtestvalue) LOINC | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.305  | HER2 Negative (geneinterpretation/Labtestvalue) NCI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.307  | HER2 Negative (geneinterpretation/Labtestvalue) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.308  | Solid Cancer Diagnosis ICD 9 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.309  | Solid Cancer Diagnosis SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.31  | HER2 Positive | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.310  | Solid Cancer Diagnosis | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.311  | Localized_Solid_Cancer_Stage Group NCIM | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.313  | Localized_Solid_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.314  | Locally_Advanced_Solid_Cancer_Stage Group NCIM | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.315  | Locally_Advanced_Solid_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.316  | Metastatic_Solid_Cancer_Stage Group NCIM | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.317  | Metastatic_Solid_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.318  | Solid Cancer T Stage LOINC | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.319  | Solid Cancer T Stage NCI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.32  | HER2 Positive | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.320  | Solid Cancer T Stage codes | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.321  | Prior_Systemic_therapy_Enhertu | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.322  | RET test_Solid_cancer (HGNC) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.323  | RET Positive_Solid_Cancer (geneinterpretation) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.324  | RET Negative_Solid_Cancer (geneinterpretation) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.325  | RET fusion Molecular Variants_Solid_Cancer | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.326  | Prior_systemic_therapy_Retevmo | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.327  | Selpercatinib (Retevmo) Drug | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.328  | Breast Cancer Diagnosis ICD9 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.329  | Breast Cancer Diagnosis ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.33  | Metastatic Breast Cancer | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.330  | Breast Cancer Diagnosis | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.331  | Metastatic_Breast_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.332  | Locally_Advanced_Breast_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.333  | Localized_Breast_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.334  | Breast cancer M Stage (metastatic) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.335  | Breast Cancer T Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.336  | Breast Cancer N Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.337  | Metastatic Sites All Breast SNOMEDCT | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.338  | Metastatic Sites All Breast ICD9 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.339  | Metastatic Sites All Breast ICD10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.340  | Metastatic Sites All Breast (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.341  | Aromatase_Inhibitor therapy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.342  | Capivasertib_therapy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.343  | Fulvestrant_therapy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.344  | PTEN_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.345  | PTEN_geneinterpretation | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.346  | PIK3CA_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.347  | PI3KCA_geneinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.348  | AKTI_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.349  | AKTI_geneinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.35  | All Metastatic Sites | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.350  | Progesterone_receptor_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.351  | Progesterone_receptor_geneinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.352  | Estrogen_receptor_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.353  | Estrogen_receptor_geneinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.354  | Progesterone_receptor_labtest | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.355  | Progesterone_receptor_labinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.356  | Estrogen_receptor_labtest | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.357  | Estrogen_receptor_labinterpretation | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.358  | NSCLC M0 Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.359  | HER2_IHC_test_Gene | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.36  | All Metastatic Sites | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.360  | HER2_IHC_test_Lab | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.361  | HER2_Fish_test | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.362  | HER2_IHC_Negative | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.363  | Trodelvy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.364  | Chemotherapy_breast_cancer | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.365  | Cyclin_dependent_kinase | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.366  | Taxane_Trodelvy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.367  | Endocrine_therapy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.368  | HER2_Fish_test_Negative | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.369  | HER2_IHC_Equivocal | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.37  | Locoregional Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.370  | HER2 Positive_PM_results | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.371  | HER2 test_Lab | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.372  | HER2 test_gene | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.374  | Thyroid Cancer Diagnosis | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.375  | Metastatic_Thyroid_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.376  | RET mutation_Molecular Variants | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.377  | RET Gene mutation | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.378  | Locally_Advanced_Localized_Thyroid_Cancer_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.379  | Thyroid cancer M1_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.38  | Locoregional Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.380  | Thyroid_cancer_M0_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.381  | Thyroid_cancer_T_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.382  | Thyroid_cancer_T1_T2_T3_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.383  | Thyroid_cancer_T4_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.384  | Thyroid_cancer_N1b_Stage&Above | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.385  | Thyroid_cancer_N_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.386  | Medullary_thyroid_histology | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.387  | RET test_Thyroid_cancer (HGNC) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.388  | RET Positive | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.389  | NSCLC N3 Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.39  | Locoregional Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.390  | CRC Cancer Diagnosis ICD9 | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.391  | CRC Cancer Diagnosis ICD10 | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.392  | CRC Cancer Diagnosis ICD9/ICD10 | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.393  | Metastatic_CRC_Cancer_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.394  | Locally_Advanced_Localized_CRC_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.395  | CRC cancer M Stage (metastatic) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.396  | CRC Cancer T Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.397  | CRC Cancer N Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.398  | KRAS_gene | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.399  | KRAS_negative | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.40  | Locoregional Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.400  | Fluoropyrimidine_CRC | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.401  | Oxaliplatin | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.402  | Irinotecan_based_therapy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.403  | anti_VEGF_therapy_CRC | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.404  | anti_EGFR_therapy_CRC | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.405  | fruquitinib | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.406  | Locally_Advanced_CRC_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.407  | Localized_CRC_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.408  | CRC cancer M0_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.409  | CRC_Cancer_T1_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.41  | All Metastatic Sites ICD910 | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.410  | CRC_Cancer_T2_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.411  | CRC_Cancer_T3_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.412  | CRC_Cancer_T4_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.413  | CRC Cancer N1 Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.414  | CRC Cancer N2 Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.415  | CRC Cancer N2b Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.416  | KRAS_G12C_MV | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.417  | KRAS_G12C_PM | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.418  | KRAS_positive | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.419  | Adagrasib | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.42  | Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.420  | cetuximab_therapy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.421  | Tamoxifen_therapy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.423  | Endometrial Cancer Diagnosis ICD 10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.425  | Endometrial Cancer Diagnosis ICD9CM | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.426  | Endometrial Cancer Diagnosis | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.428  | Localized_Endometerial_Stage Group SNOMED | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.429  | Localized_Endometerial_Stage Group NCIM | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.43  | Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.431  | Endometrial_Sarcoma_Tumor_Histology_exc | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.432  | Endometrial cancer M Stage (metastatic) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.433  | Endometrial_M0_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.436  | Prior_therapy_Endometrial | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.437  | Paclitaxel_therapy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.44  | Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.441  | Carboplatin_therapy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.442  | Durvalumab_therapy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.444  | MMR_Gene_Lab_LOINC | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.447  | MMR_Gene_HGNC | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.449  | Endometrial_ Cancer N Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.45  | Endometrial Cancer ICD9 | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.451  | Endometrial_N0_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.453  | Endometrial_N1_N2_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.455  | Endometrial_T1_T3_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.456  | Endometrial_T3_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.458  | Endometrial_T4_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.459  | Endometrial Cancer T Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.46  | Endometrial Cancer ICD10 | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.460  | Localized_Endometerial_Stage Group_SNOMED/NCIM | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.461  | Metastatic Sites All CRC | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.462  | Metastatic Sites All CRC ICD 10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.463  | Metastatic Sites All CRC ICD 9 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.464  | Metastatic Sites All CRC (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.465  | NTRK Repotrectinib Molecular Variants | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.466  | NTRK_Gene_rearrangment | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.467  | Prior_Systemic_therapy_Repotrectinib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.468  | NTRK_Positive | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.469  | NTRK_test_gene | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.47  | Systemic treatment for endometrial cancer | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.470  | Tamoxifen_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.471  | Toremifene_trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.472  | Fulvestrant_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.473  | Elacestrant | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.474  | Anastrozole_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.475  | Leuprolide_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.476  | Abemaciclib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.477  | Palbociclib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.478  | Ribociclib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.479  | Carboplatin_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.48  | Endometrial Cancers | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.480  | Cisplatin_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.481  | Cyclophosphamide | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.482  | Methotrexate | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.483  | Gemcitabine | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.484  | Capecitabine | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.485  | Eribulin | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.486  | Doxorubicin | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.487  | Vinorelbine | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.488  | Epirubicin | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.489  | Ixabepilone | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.49  | MSI Testing | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.490  | Olaparib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.491  | Talazoparib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.492  | Entrectinib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.493  | larotrectinib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.494  | Alpelisib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.495  | Capivasertib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.496  | Pembrolizumab | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.497  | Dostarlimab | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.498  | Selpercatinib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.499  | Everolimus | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.50  | MSI High | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.500  | Trastuzumab_deruxtecan | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.501  | Test 23 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.502  | All Metastatic sites Endometrial SNOMED | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.503  | All Metastatic sites Endometrial ICD9 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.504  | All Metastatic sites Endometrial ICD10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.505  | All Metastatic sites Endometrial | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.506  | Create CRC_Cancer_T4a_Stage | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.507  | Create CRC_Cancer_T4b_Stage | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.508  | High Emetogenic Risk Chemotherapy | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.510  | InactiveFollowup | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.53  | MMR Gene Testing | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.54  | MSI High | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.55  | MSI High | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.56  | Early and Limited Stage | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.57  | Early Stage IIB or lower | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.58  | MMR Deficient | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.59  | MMR Deficient | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.6  | Orserdu | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.60  | MMR Deficient | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.61  | Stage IIB or lower and limited | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.62  | Stage III or higher | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.63  | Stage III or higher | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.64  | Stage III or higher | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.65  | Staging Unknown | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.66  | Staging Unknown | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.67  | Staging Unknown | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.68  | Jemperli | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.69  | Uterine Sarcoma | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.7  | Her2 Test For Orserdu | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.70  | Tumor Histology | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.71  | Platinum based therapy | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.72  | Prior Therapies for Tucatinib | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.73  | Tucatinib | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.74  | Colorectal Cancer ICD10 | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.75  | Colorectal Cancer ICD9 | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.76  | Colorectal Cancer ICD9 and ICD10 | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.78  | Advanced or Unresectable Colorectal Cancer Staging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.79  | 0 to IIIB Colorectal Cancer Staging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.80  | Colorectal Cancer M1 Stage | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.81  | RAS Genes | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.82  | RAS Gene Interpretation Negative LOINC | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.83  | RAS Gene Interpretation Negative SNOMED | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.84  | RAS Gene Interpretation Negative NCM | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.85  | RAS Gene Negative | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.86  | RAS Gene Interpretation Positive SNOMED | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.87  | RAS Gene Interpretation Positive LOINC | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.88  | RAS Gene Positive | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.89  | Her2 Testing | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.9  | ER Test for Orserdu | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.90  | Patient Reason | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.91  | MSI High NCI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.92  | MSI Low SNOMED | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.93  | MSI Low LOINC | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.94  | MSI Low NCI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.95  | MSI Low | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.96  | MMR Deficient NCI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.97  | MMR Proficient SNOMED | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.98  | MMR Proficient LOINC | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.99  | MMR Proficient NCI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1262.3  | ICD9 Codes for HIV Diagnosis | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.1  | Inpatient Pneumonia Diagnosis | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.11  | Chest Imaging for Pneumonia, HCPCS | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.12  | Chest Imaging for Pneumonia Grouping Definition | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.18  | ICD9 Abnormal Finding on Chest Imaging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.19  | ICD10 Abnormal Finding on Chest Imaging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.2  | ICD9 Pneumonia Definition | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.20  | SNOMEDCT Abnormal Finding on Chest Imaging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.21  | Abnormal Finding on Chest Imaging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.22  | SNOMEDCT Pneumonia Definition | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.23  | CAP Concurrent Infections | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.24  | CAP Pneumonia Diagnostic | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.25  | Antibiotic Usage for CAP Diagnosis | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.27  | Legionella Presence by Urine Antigen or DNA | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.29  | Broad Spectrum Antibiotics for MDRO | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.3  | ICD10 Pneumonia Definition | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.32  | CPT Transplants, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.33  | HCPCS Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.34  | ICD10CM Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.35  | ICD10PCS Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.37  | SNOMEDCT Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.38  | Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.39  | Antibiotic Usage for CAP Duration | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.40  | CAP Sepsis Diagnostic | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.41  | CAP Respiratory Failure Diagnostic | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.42  | MRSA Organism or Substance in Lab Results | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.8  | Systemic Antimicrobials | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.9  | Chest Imaging for Pneumonia, CPT | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.1  | Problem Type | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.10  | Information Source for Medication Adherence HSLOC | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.11  | Information Source for Medication Adherence | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.13  | Screening and Assessment Survey Codes | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.14  | Unknown and Asked but Unknown (DAR) | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.15  | Yes or No SCT | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.16  | Answer Set with Yes No and Unknowns | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.17  | Common LOINC Lab Codes | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.18  | Radiology Procedures (LOINC) | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.19  | Clinical Tests | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.21  | Universal Common LOINC Lab Orders | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.22  | Route of Administration of Therapeutic Agents | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.23  | Encounter Type | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.24  | Specimen Condition SCT | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.25  | Detailed race including absence reasons. | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.26  | Healthcare Facility type (SCT) | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.27  | Social History Type (LOINC) | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.28  | Social History Type | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.29  | Encounter Type CPT | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.3  | Smoking status comprehensive | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.31  | Healthcare Service Location Type Combined | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.4  | Smoking Status Type LOINC | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.5  | Smoking Status Pack Years SCT | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.6  | Smoking Status Type | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.7  | Information Source for Medication Adherence HL7 Role Code | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.8  | Information Source for Medication Adherence ParticpationFunction | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.9  | Information Source for Medication Adherence SCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.1  | Malnutrition | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.10  | Fracture | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.11  | Transplant Diagnoses | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.13  | Transplant Diagnoses ICD10CM | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.14  | Transplant Diagnoses SNOMED CT | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.15  | Respiratory Procedures | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.2  | Moderate Injuries (SNOMEDCT) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.3  | Diabetes | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.4  | Diabetes | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.5  | Diabetes | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.6  | Immobility | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.7  | Smoking status | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.8  | Obesity | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.9  | Hormone Therapy | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.1  | Drug Intervention Not Indicated/Contraindicated | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.10  | Endotracheal Intubation | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.2  | Procedure Not Indicated/Contraindicated | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.9  | Mechanical Circulatory Assist Device | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.1  | RXNormSBD0305 | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.2  | RXNormSCD0305 | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.4  | Sequential Organ Failure Assessment SOFA | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.5  | Septic Shock | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.6  | Septic Shock | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.1  | Administrative Gender (HL7 V3) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10267  | ParticipationFunction | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10416  | Financially Responsible Party Type Value Set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10612  | Unknown Null | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10637  | PostalAddressUse | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10901  | ParticipationType | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.11610  | x_ActRelationshipDocument | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12199  | LanguageAbilityProficiency | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12212  | Marital Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12249  | LanguageAbilityMode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.14914  | Race Value Set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.15913  | EntityNameUse | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.16926  | HL7 BasicConfidentialityKind | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.18877  | Coverage Role Type Value Set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19185  | Religious Affiliation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19563  | Personal Relationship Role Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19579  | Family Member Value | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19601  | x_ServiceEventPerformer | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19717  | No Immunization Reason | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.12  | HealthStatus | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.3  | ReferralDocumentType | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.4  | TransferDocumentType | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.5  | Wound Measurements | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.6  | Wound Type | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.7  | Nutritional Status | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.9  | Nutrition Recommendations | active | 2018-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2  | Advance Directive Type Code | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.22  | HPDocumentType | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20275  | HealthcareServiceLocation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20549  | Criticality Observation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.78  | Observation Interpretation (HL7) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.1  | Initial Case Report Trigger Code Result Status | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.12  | Therapeutic Response to Medication | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.300  | Transmission Based Precaution Types | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.304  | Organism | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.305  | Microbiology and Antimicrobial Susceptibility Tests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.306  | Infectious Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.2  | Codes for MDRO and CDI Summary Data LTCF | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.3  | NHSNPrimaryResidentServiceType | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.4  | Codes for Denominators for Long Term Care Locations LTCF | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.5  | Codes for Prevention Process Measures LTCF | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.9.1  | NHSNReportNoEventsMDROLTCF | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.10  | Codes for Healthcare Personnel Influenza Vaccination (HP FLU) Summary Data | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.11  | Codes for Hemovigilance (HV) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.12  | Codes for Intensive Care Unit (ICU) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.13  | Codes for Neonatal Intensive Care Unit (NICU) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.15  | Codes for Prevention Process and Outcome Measures (POM) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.16  | Codes for Specialty Care Area (SCA) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.17  | Codes for Vascular Access Type (Dialysis) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.18  | NHSNReportNoEventsICU | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.19  | NHSNReportNoEventsNICU | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.20  | NHSNReportNoEventsSCA | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.21  | NHSNReportNoEventsMDRO | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.22  | NHSNReportNoEventsDialysis | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.24  | NHSNVascularSpecimenCollectionSite | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.29  | NHSNSSIDetectionMethod | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.3  | NHSNLastLocationEncounterTypeCode | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.30  | NHSNLOS/MENDischargeDisposition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.31  | NHSNSSIDetectionMethodType | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.32  | Codes for Outpatient Procedure Component Same Day Outcome Measures Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.33  | NHSNReportNoEventsOPCSameDayOutcomeMeasures | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.34  | NHSNOPCProcedureCategoryCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.35  | NHSNReportNoEventsAR | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.4  | NHSNDrugSusceptibilityTestMethod | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.40  | NHSN COVID19 Case Classification | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.5  | NHSN Pathogen Reduced Apheresis Platelet Usage | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.50  | NHSNGenotypicTestInterpretation | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.6  | HealthcarePersonnelType | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.7  | NHSNInfluenzaVaccinationSetting | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.8  | Codes for Antimicrobial Resistance Option (ARO) Summary Data | active | 2020-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.9  | Codes for Antimicrobial Usage, Pharmacy (AUP) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.1.1  | SurgicalOperationNoteDocumentTypeCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.12.1  | Personal And Legal Relationship Role Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.4.1  | DischargeSummaryDocumentTypeCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.6.1  | ProcedureNoteDocumentTypeCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.7.1  | SupportedFileFormats | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.8.1  | ProgressNoteDocumentTypeCode | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.18  | MoodCodeEvnInt | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.19  | ProblemAct statusCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.20  | Telecom Use (US Realm Header) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.21  | AgePQ_UCUM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.22  | ProcedureAct statusCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.23  | Planned moodCode (Act/Encounter/Procedure) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.24  | Planned moodCode (SubstanceAdministration/Supply) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.25  | Planned moodCode (Observation) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.26  | EntityPersonNamePartQualifier | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.29  | DIRQuantityMeasurementTypeCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.31  | ConsultDocumentType | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.32  | DIRDocumentTypeCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.33  | INDRoleclassCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.34  | Patient Education | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.35  | Pressure Ulcer Stage | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.36  | Pressure Point | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.37  | TargetSite Qualifiers | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.38  | Smoking Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.39  | Result Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.41  | Tobacco Use | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.44  | Mental and Functional Status Response | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.46  | Ability | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.47  | ADL Result Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.49  | Residence and Accommodation Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.50  | Sensory Status Problem Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.51  | Healthcare Agent Qualifier | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.52  | Encounter SCT | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.54  | Planned Intervention moodCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.55  | Goal Achievement | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.56  | Referral Types | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.58  | Wound Characteristic | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.59  | DIRSectionTypeCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.60  | Priority Level | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.61  | Care Model | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.62  | Related Document (append/replace) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.65  | Physical Exam Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.66  | Patient Referral Act moodCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.68  | Note Types | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.1  | Advance Care Planning Services CPT | active | 2018-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.2  | Advance Care Planning Services SCT | active | 2018-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.3  | Advance Care Planning Services Grouping | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.17  | Obligation or Prohibition Instruction Type | active | 2018-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.4  | Advance Healthcare Directive Categories LOINC | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.5  | Advance Directives Content Types | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.6  | Planned or Completed moodCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.7  | Obligation or Prohibition Instruction Type | active | 2017-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.80  | Pregnancy Status Determination Method | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.81  | Estimated Date of Delivery Including Method | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.82  | Estimated Gestational Age Code Including Method | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.84  | Other Pregnancy Outcome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.86  | Pregnancy Outcome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.87  | Postpartum Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.88  | Pregnancy Related Findings | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.89  | D(Rh) Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.90  | D(Rh) Sensitized | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.91  | Rho(D) Immune Globulin | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.1  | NHSNEncounterTypeCode | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.10  | NHSNASAClassCode | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.11  | NHSNSpinalFusionLevelCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.12  | NHSNOccasionOfDetectionCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.13  | NHSNDrugSusceptibilityFindingCode | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.15  | NHSNDrugSusceptibilityTestsCode | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.16  | NHSNPathogenCode | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.17  | NHSNProcedureCategoryCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.19  | NHSNHealthcareServiceLocationCode | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.2  | NHSNSpinalFusionApproachCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.20  | NHSNInfectionTypeCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.3  | NHSNHipReplacementCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.4  | NHSNKneeReplacementCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.6  | NHSNInfectionRiskFactorsCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.7  | NHSNBloodStreamInfectionEvidenceTypeCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.9  | NHSNWoundClassCode | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.17.4077.2.1017  | Closed Head and Facial Trauma | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.17.4077.2.1018  | Closed Head and Facial Trauma | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.1  | Major Surgical Procedure | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.134  | Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.136  | Perforation of Uterus | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.137  | Uterine Window | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.138  | Uterine Rupture | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.200  | Anticoagulant Therapy | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.201  | Antithrombotic Therapy Anticoagulant | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.202  | Atrial Fibrillation or Flutter | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.203  | Atrial Ablation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.204  | Carotid Intervention | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.205  | Direct Thrombin Inhibitor | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.207  | Discharged to Health Care Facility for Hospice Care | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.209  | Discharged to Home for Hospice Care | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.211  | Injectable Factor Xa Inhibitor for VTE Prophylaxis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.212  | Hemorrhagic Stroke | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.213  | INR | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.214  | Intermittent pneumatic compression devices | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.215  | LDLc | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.218  | Unfractionated Heparin | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.219  | Low Molecular Weight Heparin for VTE Prophylaxis | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.222  | Intravenous route | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.223  | Subcutaneous route | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.226  | Thrombolytic tPA Therapy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.230  | Venous foot pumps | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.232  | Warfarin | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.234  | Hemorrhagic Stroke | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.235  | Hemorrhagic Stroke | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.238  | Carotid Intervention | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.239  | Carotid Intervention | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.242  | Atrial Ablation | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.243  | Atrial Ablation | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.244  | Atrial Fibrillation or Flutter | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.245  | Atrial Fibrillation or Flutter | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.246  | Atrial Fibrillation or Flutter | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.247  | Ischemic Stroke | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.25  | Single Live Birth | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.251  | Ischemic Stroke Embolism | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.252  | Ischemic Stroke Embolism | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.255  | General Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.256  | Graduated compression stockings | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.257  | Gynecological Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.258  | Hip Fracture Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.259  | Hip Replacement Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.26  | Single Live Born Newborn Born in Hospital | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.260  | Intracranial Neurosurgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.261  | Knee Replacement Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.263  | Obstetrical or Pregnancy Related Conditions | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.264  | Obstetrics VTE | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.27  | Dietary Intake Other than Human Milk | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.270  | Acute or Persistent Asthma | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.271  | Acute or Persistent Asthma | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.272  | Urological Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.279  | Venous Thromboembolism | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.281  | Labor | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.282  | Cesarean Birth | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.286  | Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.288  | Medical Induction of Labor | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292  | Emergency Department Visit | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.294  | Decision to Admit to Hospital Inpatient | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.295  | Decision to Admit to Hospital Inpatient | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.296  | Psychiatric/Mental Health Diagnosis | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.298  | Psychiatric/Mental Health Diagnosis | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.299  | Psychiatric/Mental Health Diagnosis | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.30  | Human Milk | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.308  | Left Against Medical Advice | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.309  | Patient Expired | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.310  | Gynecological Surgery | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.313  | Gynecological Surgery | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.315  | Knee Replacement Surgery | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.317  | Knee Replacement Surgery | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.319  | Hip Replacement Surgery | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.321  | Hip Replacement Surgery | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.323  | Hip Fracture Surgery | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.325  | Hip Fracture Surgery | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.328  | Venous Thromboembolism | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.33  | Galactosemia | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.330  | Venous Thromboembolism | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.331  | Urological Surgery | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.333  | Urological Surgery | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.335  | Obstetrical or Pregnancy Related Conditions | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.337  | Obstetrical or Pregnancy Related Conditions | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.338  | Obstetrics VTE | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.340  | Obstetrics VTE | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.344  | Intracranial Neurosurgery | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.346  | Intracranial Neurosurgery | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.348  | General or Neuraxial Anesthesia | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.35  | Galactosemia | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.361  | General Surgery | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.365  | General Surgery | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.367  | Cesarean Birth | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.369  | Cesarean Birth | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.37  | Parenteral Nutrition | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.38  | Parenteral Nutrition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.384  | Medical Induction of Labor | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.393  | Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.395  | Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.400  | Low Risk | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.401  | Delivery Procedures | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.418  | Classical Cesarean Birth | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.419  | Classical Cesarean Birth | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.421  | Classical Cesarean Birth | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.422  | Myomectomy | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.423  | Statin Allergen | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.424  | Nonelective Inpatient Encounter | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.473  | Medical Reason For Not Providing Treatment | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.75  | Neonatal Intensive Care Unit | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.76  | Single Live born Newborn | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.78  | Galactosemia | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.79  | Parenteral Nutrition | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.87  | Discharge To Acute Care Facility | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.93  | Patient Refusal | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1434.1047  | Skin Melanoma pT1 | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.100  | Injectable Fluorouracil | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.101  | Trastuzumab and Biosimilars | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.102  | Breast Cancer | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.103  | HER2 Presence in Tissue | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.104  | Depression Screening for Adult | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.105  | Long Acting Opioids | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.106  | High Fiber Supplement or Diet Education | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.107  | Standardized Assessment Tools for Dyspnea | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.108  | Nausea or Vomiting Assessment | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.109  | Pancreatic Cancer | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.110  | Pancreatic Cancer | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.111  | Audio Visual Telehealth Encounter | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.112  | Telephone Encounter | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.113  | Telehealth Emergency Department or Initial Inpatient | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.114  | Karnofsky Performance Status | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.115  | Referral to Hospice Care | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.116  | Referral to Palliative Care | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.117  | Assessment Scale for Dyspnea | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.118  | Nausea or Vomiting Assessment | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.119  | Enrollment in Hospice Care | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.120  | Palliative Care | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.121  | Advance Directive Including Durable Power of Attorney or Instructional | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.122  | Carmustine Injectable | active | 2022-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.123  | Dacarbazine Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.124  | Streptozocin Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.126  | Alemtuzumab Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.127  | Azacitidine Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.128  | Bendamustine Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.129  | Busulfan Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.130  | Temozolomide Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.131  | Thiotepa Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.132  | Oxaliplatin Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.133  | Romidepsin Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.134  | Trabectedin Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.135  | Dolasetron Oral | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.136  | Dolasetron Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.137  | Granisetron Oral | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.138  | Granisetron Transdermal | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.139  | Granisetron Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.140  | Ondansetron Oral | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.141  | Ondansetron Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.142  | Ifosfamide Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.143  | Arsenic Trioxide Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.144  | Netupitant Palonosetron Oral | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.145  | Fosnetupitant Palonosetron Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.146  | Aprepitant Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.147  | Rolapitant Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.148  | Dexamethasone Oral | active | 2022-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.149  | Dexamethasone Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.150  | Dexamethasone Drug Implant | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.151  | Olanzapine Oral | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.152  | Olanzapine Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.153  | Idarubicin Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.154  | Neurokinin 1 Receptor Antagonist Ingredient | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.155  | Serotonin Receptor Antagonist Ingredient | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.156  | Clofarabine Injectable | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.157  | Belinostat Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.158  | Bortezomib Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.159  | Cabazitaxel Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.160  | Carfilzomib Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.161  | Decitabine Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.162  | Elotuzumab Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.163  | Enfortumab Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.164  | Eribulin Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.165  | Etoposide Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.166  | Inotuzumab Ozogamicin Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.167  | Mitoxantrone Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.168  | Moxetumomab Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.169  | Necitumumab Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.170  | Nelarabine Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.171  | Temsirolimus Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.172  | Tisagenlecleucel Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.173  | Topotecan Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.178  | Atezolizumab Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.179  | Avelumab Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.180  | Bleomycin Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.181  | Cemiplimab Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.182  | Cladribine Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.183  | Daratumumab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.184  | Durvalumab Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.185  | Emapalumab Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.186  | Fludarabine Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.187  | Ipilimumab Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.188  | Nivolumab Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.189  | Pembrolizumab Injectable | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.190  | Polatuzumab Vedotin Injectable | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.191  | Pralatrexate Injectable | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.192  | Vincristine Injectable | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.193  | Methotrexate Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.194  | Trastuzumab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.195  | Mitomycin Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.196  | Brentuximab Vedotin Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.197  | Doxorubicin Pegylated Liposomal Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.198  | Blinatumomab Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.199  | Trastuzumab Emtansine Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.200  | Gemtuzumab Ozogamicin Injectable | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.201  | Tagraxofusp Injectable | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.202  | Axicabtagene Ciloleucel Injectable | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.203  | BRCA1 | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.204  | BRCA2 | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.205  | BRCA1 Testing | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.207  | Epithelial Ovarian Cancer | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.208  | Primary Peritoneal Cancer | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.209  | Fallopian Tube Cancer | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.210  | Multigene Panel | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.211  | BRCA1 and BRCA2 | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.212  | BRCA1 and BRCA2 Testing | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.213  | BRAF V600 | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.214  | BRAF V600 Testing | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.215  | Colorectal Cancer | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.216  | BRAF V600 Mutation Status | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.217  | Cancer Stage I | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.218  | Head and Neck Cancer | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.219  | Malignant Melanoma of Skin | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.220  | Brain Cancer | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.221  | Waldenstrom Macroglobulinemia | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.222  | High Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.223  | Moderate Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.224  | Docetaxel Injectable | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.225  | Cyclophosphamide Injectable | active | 2022-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.226  | LAG 3 Inhibitor | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.227  | Neoplasm of Brain | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.233  | Chemotherapy Administration | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.240  | Pathological N Stage N3c | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.241  | Audio Visual Telehealth Encounter | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.242  | Moderate or High Emetic Risk Oral Antineoplastic Agent | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.243  | Minimal to Low Emetic Risk Oral Antineoplastic Agent | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.244  | Copanlisib Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.245  | Isatuximab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.246  | Loncastuximab tesirine Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.247  | Margetuximab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.248  | Mirvetuximab soravtansine Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.249  | Tafasitamab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.250  | Teclistamab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.251  | Tisotumab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.252  | Asparaginase Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.254  | Belantamab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.255  | Dostarlimab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.256  | Mosunetuzumab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.257  | Tremelimumab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.258  | Indication for Dexamethasone | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.260  | Indication for Olanzapine | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.261  | Indication for Dexamethasone | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.263  | Indication for Olanzapine | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.264  | Prednisone | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.265  | As Needed PRN | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.266  | Amivantamab Injectable | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.200  | Doxorubicin | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.201  | Epirubicin | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.202  | Capecitabine | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.203  | Cyclophosphamide | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.204  | Injectable Fluorouracil | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.205  | Methotrexate | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.206  | Trastuzumab and Biosimilars | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.207  | HER2 Presence in Tissue | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.208  | Carboplatin | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.209  | Depression Screening for Adult | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.210  | Long Acting Opioids | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.211  | High Fiber Supplement or Diet Education | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.212  | Dexamethasone | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.213  | Olanzapine | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.214  | Pancreatic Cancer | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.215  | Audio Visual Telehealth Encounter | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.216  | Telephone Encounter | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.217  | Telehealth Emergency Department or Initial Inpatient | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.218  | Dyspnea Assessment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.219  | Nausea or Vomiting Assessment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.220  | Karnofsky Performance Status | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.221  | Referral to Hospice Care | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.222  | Referral to Palliative Care | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.223  | Palliative Care | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.224  | Enrollment in Hospice Care | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.225  | Advance Directive Including Durable Power of Attorney or Instructional | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.228  | Low Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.229  | Minimal Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.232  | Epithelial Ovarian Cancer | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.233  | Primary Peritoneal Cancer | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.235  | BRCA2 Testing | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.236  | Multigene Panel | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.237  | BRCA1 Testing | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.238  | First Line Drug Therapy for Metastatic Colorectal Cancer | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.239  | BRAF V600 Testing | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.240  | Cancer Stage 4 | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.241  | Cancer Stage M1 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.242  | High Emetic Risk Intravenous Antineoplastic Agent | active | 2022-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.243  | Moderate Emetic Risk Intravenous Antineoplastic Agent | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.244  | Anthracycline Injectable | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.245  | Antiemetic Agent | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.247  | Indication for Dexamethasone | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.249  | Indication for Olanzapine | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.2074.1.1.3  | Race Category Excluding Nulls | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1  | Abdomen CT without contrast | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.11  | Oxycodone | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.12  | Oxymorphone | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.70  | Morphine | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.71  | Methadone Medications | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.72  | Meperidine | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.73  | Levorphanol | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.74  | Hydromorphone | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.75  | Hydrocodone | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.76  | Fentanyl | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.77  | Codeine | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.12  | Butorphanol | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.13  | Dihydrocodeine | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.14  | Nalbuphine | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.15  | Opium Combinations | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.16  | Pentazocine | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.17  | Tapentadol | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.18  | Tramadol | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1017  | Adrenal Mass | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1019  | Diseases of Urinary System | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1020  | Hematuria | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1021  | Infections of Kidney | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1022  | Jaundice | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1023  | Liver Lesion (Mass or Neoplasm) | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1024  | Malignant Neoplasm of Bladder | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1025  | Malignant Neoplasm of Pancreas | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1026  | Non Traumatic Aortic Disease | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1028  | Unspecified Disorder of Kidney and Ureter | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1301  | Surgery Integumentary System Breast | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1302  | Surgery Respiratory System Accessory Sinuses | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1303  | Surgery Respiratory System Larynx | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1304  | Surgery Respiratory System Trachea and Bronchi | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1305  | Surgery Respiratory System Lungs and Pleura | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13064  | Surgery Digestive System Esophagus | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1307  | Surgery Digestive System Intestines (Except Rectum) | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1308  | Surgery Digestive System Rectum | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1309  | Surgery Digestive System Anus | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1310  | Surgery Digestive System Biliary Tract | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1311  | Surgery Digestive System Abdomen Peritoneum Omentum | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1312  | Surgery Digestive System Kidney | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13133  | Surgery Digestive System Ureter | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1314  | Surgery Digestive System Bladder | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1315  | Surgery Female Genital System Cervix Uteri | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1316  | Surgery Female Genital System Corpus Uteri | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1317  | Surgery Female Genital System Oviduct Ovary | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1318  | Surgery Eye and Ocular Adnexa Anterior Segment | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13193  | Other Surgeries | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13202  | SPECT MPI | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13213  | Stress Echocardiography | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13222  | Stress MRI | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1323  | CCTA | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1329  | Diabetes Mellitus | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1330  | Renal insufficiency | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1331  | Stroke transient ischemic attack | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1332  | Prior heart failure | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1333  | Ischemic heart disease | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1802  | Physical Therapy | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1803  | Chiropractic Evaluation | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1804  | Claim(s) for evaluation and management > 28 days and <60 days preceding the lumbar spine MRI | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1805  | MRI Lumbar Spine Procedures | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1809  | Other Deforming Dorsopathies | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1810  | Spondylopathies | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1811  | Other Dorsopathies | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1812  | Biomechanical Lesions (not Elsewhere Classified) | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1813  | Dislocation or Sprain of those Joints and Ligaments Located in the Lumbar Spine or Pelvis | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.18143  | Patients with lumbar spine surgery in the 90 days prior to MRI | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1832  | Cancer | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1833  | Congenital spine and spinal cord malformations | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1834  | Inflammatory and autoimmune disorders | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1835  | Infectious conditions | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1836  | Spinal vascular malformations and/or the cause of occult subarachnoid hemorrhage | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1837  | Spinal cord infarction | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1838  | Neoplastic abnormalities | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1839  | Treatment fields for radiation therapy | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1840  | Spinal abnormalities associated with scoliosis | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1841  | Syringohydromyelia | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1842  | Postoperative fluid collections and soft tissue changes | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1843  | Trauma | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1844  | IV Drug Abuse | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1845  | Neurological Impairment | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1846  | Human Immunodeficiency Virus | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1847  | Unspecified Immune Deficiencies | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.190123  | Diagnostic Mammography Study | active | 2018-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1902  | Ultrasound of the Breast | active | 2019-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.190412  | Screening Mammography and DBT Studies | active | 2018-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2  | Abdomen CT with contrast | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.1  | Percutaneous Coronary Intervention ICD10 | active | 2018-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.2  | Percutaneous Coronary Intervention SNOMEDCT | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.3  | Percutaneous Coronary Intervention CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.4  | Percutaneous Coronary Intervention HCPCS | active | 2018-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.5  | Percutaneous Coronary Intervention | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.21  | Abdomen CT Without then With Contrast | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4009  | Malignant Intracranial Neoplasm | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4010  | Malignant Intracranial Neoplasm | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4015  | STEMI | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4016  | STEMI | active | 2019-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4017  | STEMI | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4019  | Fibrinolytic Therapy | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4023  | Cerebral Vascular Lesion | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4024  | Cerebral Vascular Lesion | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4025  | Cerebral Vascular Lesion | active | 2019-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4026  | Closed Head and Facial Trauma | active | 2019-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4028  | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4029  | Acute Peptic Ulcer | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4030  | Acute Peptic Ulcer | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4031  | Acute Peptic Ulcer | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4032  | Dementia and Related Intracranial Pathologies | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4033  | Dementia and Related Intracranial Pathologies | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4034  | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4035  | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4036  | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4043  | Dementia and Related Intracranial Pathologies | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4044  | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4045  | Oral Anticoagulant Medications | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4046  | Cardiopulmonary Emergency | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4047  | Cardiopulmonary Emergency | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4048  | Cardiopulmonary Emergency | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4049  | Mechanical Circulatory Assist Device | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4050  | Mechanical Circulatory Assist Device | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4052  | Mechanical Circulatory Assist Device | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4053  | Pregnant State | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4054  | Pregnant State | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4055  | Pregnant State | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4056  | Major Surgical Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4057  | Emergency Department Encounter | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4066  | Diagnostic DBT Study | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.2.1005  | Chronic Stable Angina | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.2.1006  | Chronic Stable Angina | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.3.1002  | Chronic Stable Angina | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1001  | Hospice Encounter | active | 2021-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1002  | Hospice Encounter | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1003  | Hospice Encounter | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1004  | Nutrition Services | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1005  | Nutrition Services | active | 2021-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1006  | Nutrition Services | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1007  | Hospice Care Ambulatory | active | 2021-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1008  | Hospice Care Ambulatory | active | 2021-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1005  | Office Visit | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1020  | Initial Hospital Inpatient Visit | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1030  | Discharge Services Hospital Inpatient Same Day Discharge | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1035  | Discharge Services Hospital Inpatient | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1040  | Outpatient Consultation | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1050  | Emergency Department Evaluation and Management Visit | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1060  | Nursing Facility Visit | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1065  | Discharge Services Nursing Facility | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1080  | Home Healthcare Services | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1110  | Preventive Care, Initial Office Visit, 0 to 17 | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1115  | Preventive Care Services Initial Office Visit, 18 and Up | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1120  | Preventive Care, Established Office Visit, 0 to 17 | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1125  | Preventive Care Services Established Office Visit, 18 and Up | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1130  | Preventive Care Services Individual Counseling | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1135  | Preventive Care Services Group Counseling | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1215  | Referral | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1216  | Face-to-Face Interaction | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1221  | Behavioral Health Follow up Visit | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1222  | Psychotherapy and Pharmacologic Management | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1228  | Detoxification Visit | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1232  | Audiology Visit | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1233  | Medical Disability Exam | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1260  | Telephone Visits | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1261  | Nursing Facility Visit | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1262  | Care Services in Long Term Residential Facility | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1264  | Office Visit | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1265  | Home Healthcare Services | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1266  | Outpatient Consultation | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1276  | Frailty Encounter | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1277  | Outpatient Encounter | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1278  | Outpatient Encounter | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1279  | Frailty Encounter | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1281  | Virtual Encounter | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1282  | Virtual Encounter | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1284  | Outpatient Encounter | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1285  | Palliative Encounter | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1286  | Palliative Encounter | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1287  | Telephone Visits | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001  | Office Visit | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1004  | Initial Hospital Inpatient Visit | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1006  | Discharge Services Hospital Inpatient Same Day Discharge | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1007  | Discharge Services Hospital Inpatient | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1008  | Outpatient Consultation | active | 2024-01 |
us.nlm | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1216  | Amputation of Right Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1217  | Amputation of Right Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1218  | Amputation of Unspecified Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1219  | Amputation of Unspecified Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.122.11.1003  | Ambulatory | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.122.12.1003  | Ambulatory | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1220  | Foot Assessment With Abnormal Result or Finding | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1221  | Foot Assessment With Abnormal Result or Finding | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1222  | Acquired Absence of Bilateral feet | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1223  | Acquired Absence of Bilateral feet | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1224  | Acquired Absence of Left Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1225  | Acquired Absence of Left Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1226  | Acquired Absence of Left Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1227  | Acquired Absence of Right Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1228  | Acquired Absence of Right Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1229  | Acquired Absence of Right Foot | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1230  | Lower Body Fractures Excluding Ankle and Foot | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1231  | Malignant Neoplasms of Lower and Unspecified Limbs | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1232  | Mechanical Complications Excluding Upper Body | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1233  | Partial Arthroplasty of Hip | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1234  | Partial Arthroplasty of Hip | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1235  | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1236  | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1237  | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1238  | Primary THA Procedure | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1239  | Foot Ulcer | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1240  | Foot Ulcer | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1241  | Foot Ulcer | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1242  | Referral for Foot Care | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1243  | Therapeutic Footwear | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1244  | Foot Deformity | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1245  | Foot Deformity | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1246  | Foot Deformity | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1247  | Megestrol Medications | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1248  | Meperidine Medications | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1249  | Potentially Harmful Antidepressants for Older Adults | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1004  | Fluoride Varnish Application for Children | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1007  | Dental Caries | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1009  | Dental Caries | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1010  | Clinical Oral Evaluation | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1011  | Fluoride Varnish Application for Children | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1002  | Fluoride Varnish Application for Children | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1003  | Clinical Oral Evaluation | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1004  | Dental Caries | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1250  | Potentially Harmful Antihistamines for Older Adults | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1251  | Potentially Harmful Antiparkinsonian Agents for Older Adults | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1252  | Potentially Harmful Barbiturates for Older Adults | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1253  | Potentially Harmful Estrogens for Older Adults | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1254  | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1255  | Potentially Harmful Pain Medications for Older Adults | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1256  | Potentially Harmful Skeletal Muscle Relaxants for Older Adults | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1257  | Potentially Harmful Sulfonylureas for Older Adults | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1258  | Substance Use Disorder Long Acting Medication | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1259  | Substance Use Disorder Short Acting Medication | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1260  | Viloxazine | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1266  | Diabetic Retinopathy Severity Level | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1272  | Diabetes | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1273  | Diabetes | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.11.1003  | Counseling for Nutrition | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.11.1004  | Counseling for Nutrition | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.12.1003  | Counseling for Nutrition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1001  | Antibiotic Medications for Pharyngitis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1078  | Nifedipine Medications | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1080  | Contraceptive Medications | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1109  | Meperidine Medications | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1129  | Desiccated Thyroid Medications | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1143  | Isotretinoin | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1167  | Dipyridamole Medications | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1205  | Leucovorin | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1211  | Aspirin and Other Antiplatelets | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1212  | DTaP Vaccine | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1214  | Hepatitis A Vaccine | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1216  | Hepatitis B Vaccine | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1220  | Child Influenza Vaccine | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1222  | Inactivated Polio Vaccine (IPV) | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1228  | Pneumococcal Conjugate Vaccine | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1232  | Rotavirus Vaccine (3 dose schedule) | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1234  | Varicella Zoster Vaccine (VZV) | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1235  | Measles, Mumps and Rubella (MMR) Vaccine | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1252  | Guanfacine Medications | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1255  | Megestrol Medications | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1256  | Meprobamate Medications | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1266  | Aromatase Inhibitors | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1267  | Glucocorticoids (oral only) | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1481  | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1482  | Potentially Harmful Antiinfectives for Older Adults | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1517  | Dementia Medications | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1530  | Antidepressant Medication | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1531  | Potentially Harmful Benzodiazepines for Older Adults | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1532  | Potentially Harmful Antipsychotics for Older Adults | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1001  | Antibiotic Medications for Pharyngitis | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1080  | Contraceptive Medications | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1143  | Isotretinoin | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1170  | Varicella Zoster Vaccine (VZV) | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1205  | Leucovorin | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1211  | Aspirin and Other Antiplatelets | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1213  | Antidepressant Medication | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1214  | DTaP Vaccine | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1215  | Hepatitis A Vaccine | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1216  | Hepatitis B Vaccine | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1218  | Child Influenza Vaccine | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1219  | Inactivated Polio Vaccine (IPV) | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1221  | Pneumococcal Conjugate Vaccine | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1223  | Rotavirus Vaccine (3 dose schedule) | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1224  | Measles, Mumps and Rubella (MMR) Vaccine | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1265  | Aromatase Inhibitors | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1266  | Glucocorticoids (oral only) | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1480  | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1481  | Potentially Harmful Antiinfectives for Older Adults | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1510  | Dementia Medications | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1522  | Potentially Harmful Benzodiazepines for Older Adults | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1523  | Potentially Harmful Antipsychotics for Older Adults | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1005  | Bilateral Mastectomy | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1009  | Primary THA Procedure | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1015  | Flexible Sigmoidoscopy | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1016  | Flexible Sigmoidoscopy | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1017  | Flexible Sigmoidoscopy | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1020  | Fecal Occult Blood Test (FOBT) | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1023  | Group A Streptococcus Test | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1024  | HbA1c Laboratory Test | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1026  | Hysterectomy with No Residual Cervix | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1027  | Hysterectomy with No Residual Cervix | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1035  | Total Colectomy | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1036  | Total Colectomy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1055  | XRay Study | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1061  | Gastric Bypass Surgery | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1062  | Gastric Bypass Surgery | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1080  | Primary THA Procedure | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1084  | History of bilateral mastectomy | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1085  | History of bilateral mastectomy | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1086  | Status Post Left Mastectomy | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1087  | Status Post Right Mastectomy | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1089  | Unilateral Mastectomy, Unspecified Laterality | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1090  | Unilateral Mastectomy, Unspecified Laterality | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1091  | Status Post Left Mastectomy | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1092  | Status Post Right Mastectomy | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1096  | Major Transplant | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1097  | Major Transplant | active | 2021-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1132  | Unilateral Mastectomy Left | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1133  | Unilateral Mastectomy Right | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1134  | Hysterectomy with No Residual Cervix | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1135  | Hysterectomy with No Residual Cervix | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1140  | Bilateral Mastectomy | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1143  | Total Colectomy | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1144  | Unilateral Mastectomy Left | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1145  | Unilateral Mastectomy Right | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1148  | Palliative Intervention | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1005  | Bilateral Mastectomy | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1006  | Primary THA Procedure | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1010  | Flexible Sigmoidoscopy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1011  | Fecal Occult Blood Test (FOBT) | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1012  | Group A Streptococcus Test | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1013  | HbA1c Laboratory Test | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1014  | Hysterectomy with No Residual Cervix | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1019  | Total Colectomy | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1034  | XRay Study | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1050  | Gastric Bypass Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1068  | History of bilateral mastectomy | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1069  | Status Post Left Mastectomy | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1070  | Status Post Right Mastectomy | active | 2017-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1071  | Unilateral Mastectomy, Unspecified Laterality | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1075  | Major Transplant | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1133  | Unilateral Mastectomy Left | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1134  | Unilateral Mastectomy Right | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135  | Palliative Care Intervention | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1064  | Anaphylactic Reaction to DTaP Vaccine | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1065  | Chronic Liver Disease | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1067  | Chronic Liver Disease | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1068  | Chronic Malnutrition | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1070  | Chronic Malnutrition | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1100  | Malabsorption Syndromes | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1102  | Malabsorption Syndromes | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1105  | Intussusception | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1106  | Intussusception | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1107  | Influenza Virus LAIV Vaccine | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1108  | Influenza Virus LAIV Vaccine Administered | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1031  | Anaphylactic Reaction to DTaP Vaccine | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1035  | Chronic Liver Disease | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1036  | Chronic Malnutrition | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1050  | Malabsorption Syndromes | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1056  | Intussusception | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2446  | Lower Extremity Visual Inspection Test | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2447  | Pedal Pulse Result or Finding | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2448  | Monofilament Test Result or Finding | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2449  | Monofilament Tests | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2450  | Lower Extremity Neurological Assessment Result or Finding | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2451  | Lower Extremity Neurological Tests | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2452  | Lower Extremity Visual Inspection Result or Finding | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2616  | Autonomous Eye Exam Result or Finding | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.1577  | Pharmacologic Therapy for Hypertension | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1036  | Chronic Kidney Disease, Stage 5 | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1037  | Chronic Kidney Disease, Stage 5 | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1049  | Patient Provider Interaction | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1058  | Psych Visit for Family Psychotherapy | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1062  | Physical Therapy Evaluation | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1063  | Occupational Therapy Evaluation | active | 2017-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1064  | Neurobehavioral Status Exam (CPT) | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1067  | Dementia and Mental Degenerations | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1068  | Dementia and Mental Degenerations | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1069  | Standardized Tools for Assessment of Cognition | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1071  | Radiation Treatment Management | active | 2017-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1072  | Radiation Treatment Management | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1073  | Standardized Pain Assessment Tool | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1078  | Cancer | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1079  | Cancer | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1080  | Chemotherapy Administration | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1081  | Chemotherapy Administration | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.111  | Ophthalmological Services | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.113  | Prostate Cancer Treatment | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.118  | Initial Myocardial Infarction | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.119  | Initial Myocardial Infarction | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.120  | Coronary Artery Disease No MI | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1238  | Ejection Fraction | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1243  | Psychoanalysis | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1244  | Renal Failure Due to ACE Inhibitor | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1251  | Group Psychotherapy | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1256  | Allergy to ACE Inhibitor or ARB | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1257  | Intolerance to ACE Inhibitor or ARB | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.133  | Beta Blocker Therapy | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1333  | Allergy to Beta Blocker Therapy | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1334  | Intolerance to Beta Blocker Therapy | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1341  | Heart Rate | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1342  | Beta Blocker Therapy for LVSD | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1344  | Acute and Subacute Iridocyclitis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1353  | Limited Life Expectancy | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1363  | Annual Wellness Visit | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1364  | Macular Exam | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1372  | Tobacco Use Screening | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1374  | Bone Scan | active | 2018-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1377  | Level of Severity of Retinopathy Findings | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1381  | Macular Edema Findings Present | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1401  | Cognitive Assessment | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1402  | Cup to Disc Ratio | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1403  | Optic Disc Exam for Structural Abnormalities | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1509  | Acute and Subacute Iridocyclitis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1521  | Burn Confined to Eye and Adnexa | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1523  | Burn Confined to Eye and Adnexa | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1524  | Cataract Secondary to Ocular Disorders | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1526  | Cataract Secondary to Ocular Disorders | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1527  | Cataract Surgery | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1528  | Cataract Surgery | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1529  | Cataract Congenital | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1530  | Cataract Congenital | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1532  | Cataract Mature or Hypermature | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1534  | Cataract Mature or Hypermature | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1535  | Cataract Posterior Polar | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1537  | Cataract Posterior Polar | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1538  | Certain Types of Iridocyclitis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1540  | Certain Types of Iridocyclitis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1542  | Chronic Iridocyclitis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1543  | Chronic Iridocyclitis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1544  | Cloudy Cornea | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1546  | Cloudy Cornea | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1548  | Corneal Edema | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1549  | Corneal Edema | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1550  | Disorders of Cornea Including Corneal Opacity | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1552  | Disorders of Cornea Including Corneal Opacity | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1561  | Glaucoma | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1562  | Glaucoma | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1564  | Hereditary Corneal Dystrophies | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1566  | Hereditary Corneal Dystrophies | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1571  | Hypotony of Eye | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1572  | Hypotony of Eye | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1574  | Injury to Optic Nerve and Pathways | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1575  | Injury to Optic Nerve and Pathways | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1577  | Central Corneal Ulcer | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1578  | Central Corneal Ulcer | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1582  | Open Wound of Eyeball | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1583  | Open Wound of Eyeball | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1587  | Pathologic Myopia | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1588  | Pathologic Myopia | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1590  | Posterior Lenticonus | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1591  | Posterior Lenticonus | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1601  | Retrolental Fibroplasias | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1603  | Retrolental Fibroplasias | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1612  | Traumatic Cataract | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1613  | Traumatic Cataract | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1615  | Uveitis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1617  | Uveitis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1618  | Vascular Disorders of Iris and Ciliary Body | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1620  | Vascular Disorders of Iris and Ciliary Body | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1621  | Visual Field Defects | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1623  | Visual Field Defects | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1626  | Amblyopia | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1628  | Amblyopia | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1632  | Choroidal Degenerations | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1634  | Choroidal Degenerations | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1635  | Choroidal Detachment | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1637  | Choroidal Detachment | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1638  | Choroidal Hemorrhage and Rupture | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1640  | Choroidal Hemorrhage and Rupture | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1641  | Degeneration of Macula and Posterior Pole | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1643  | Degeneration of Macula and Posterior Pole | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1644  | Degenerative Disorders of Globe | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1646  | Degenerative Disorders of Globe | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1647  | Diabetic Macular Edema | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1649  | Diabetic Macular Edema | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1653  | Disorders of Optic Chiasm | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1655  | Disorders of Optic Chiasm | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1656  | Disorders of Visual Cortex | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1658  | Disorders of Visual Cortex | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1659  | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1661  | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1662  | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1664  | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1665  | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1667  | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1668  | Hereditary Choroidal Dystrophies | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1670  | Hereditary Choroidal Dystrophies | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1671  | Hereditary Retinal Dystrophies | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1673  | Hereditary Retinal Dystrophies | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1677  | Nystagmus and Other Irregular Eye Movements | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1679  | Nystagmus and Other Irregular Eye Movements | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.168  | Cardiac Surgery | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1680  | Optic Atrophy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1682  | Optic Atrophy | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1683  | Optic Neuritis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1685  | Optic Neuritis | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1686  | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1688  | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1689  | Other Background Retinopathy and Retinal Vascular Changes | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.169  | Cardiac Surgery | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1691  | Other Background Retinopathy and Retinal Vascular Changes | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1695  | Other Disorders of Optic Nerve | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1697  | Other Disorders of Optic Nerve | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1701  | Other Endophthalmitis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1703  | Other Endophthalmitis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1707  | Prior Penetrating Keratoplasty | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1709  | Prior Penetrating Keratoplasty | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1713  | Purulent Endophthalmitis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1715  | Purulent Endophthalmitis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1716  | Retinal Detachment with Retinal Defect | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1718  | Retinal Detachment with Retinal Defect | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1719  | Retinal Vascular Occlusion | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1721  | Retinal Vascular Occlusion | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1722  | Other Proliferative Retinopathy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1724  | Other Proliferative Retinopathy | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1728  | Separation of Retinal Layers | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1730  | Separation of Retinal Layers | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1731  | Visual Acuity 20/40 or Better | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.175  | Hypotension | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1752  | Speech and Hearing Evaluation | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.176  | Arrhythmia | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1766  | Morgagnian Cataract | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1767  | Morgagnian Cataract | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1769  | Macular Scar of Posterior Polar | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.177  | Atrioventricular Block | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1770  | Macular Scar of Posterior Polar | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1771  | Ophthalmological Services | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1772  | Annual Wellness Visit | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1773  | Speech and Hearing Evaluation | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1774  | Occupational Therapy Evaluation | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1775  | Behavioral Neuropsych Assessment | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1776  | Psych Visit Diagnostic Evaluation | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1777  | Psych Visit Psychotherapy | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1778  | Psychoanalysis | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1779  | Group Psychotherapy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.178  | Cardiac Pacer in Situ | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1780  | Psych Visit for Family Psychotherapy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1781  | Best Corrected Visual Acuity Exam Using Snellen Chart | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1782  | Physical Therapy Evaluation | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.180  | Hypotension | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.181  | Arrhythmia | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.183  | Cardiac Pacer in Situ | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.185  | Hypotension | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.186  | Arrhythmia | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.187  | Atrioventricular Block | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1912  | Major Depressive Disorder Active | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1918  | Major Depressive Disorder Active | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1921  | Beta Blocker Therapy Ingredient | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1923  | Psych Visit Diagnostic Evaluation | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1924  | Cardiac Pacer in Situ | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.408  | Bradycardia | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.410  | Bradycardia | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.411  | Bradycardia | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.422  | Tobacco User | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.423  | Tobacco Use Cessation Pharmacotherapy | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.424  | Tobacco Use Cessation Counseling | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.425  | Tobacco Use Cessation Counseling | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.450  | Pain Warranting Further Investigation for Prostate Cancer | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.469  | Bilateral Oophorectomy | active | 2017-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.470  | Bilateral Oophorectomy | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.483  | Chemotherapy | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.484  | Chemotherapy | active | 2021-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.511  | Tobacco Non User | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.532  | Pregnancy | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.56  | Coronary Artery Disease No MI | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.57  | Coronary Artery Disease No MI | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.58  | Initial Myocardial Infarction | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.589  | End Stage Renal Disease | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.59  | Asthma | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.590  | End Stage Renal Disease | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.60  | Asthma | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.61  | Asthma | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.73  | Primary Open Angle Glaucoma | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.74  | Primary Open Angle Glaucoma | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.76  | Diabetic Retinopathy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.80  | Diabetic Retinopathy | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.859  | Left Ventricular Systolic Dysfunction | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.860  | Moderate or Severe | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.861  | Moderate or Severe LVSD | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.91  | Prostate Cancer | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.92  | Prostate Cancer | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1002  | Chronic Kidney Disease, Stage 5 | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1005  | Dementia and Mental Degenerations | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1006  | Standardized Tools Score for Assessment of Cognition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1007  | Medical Reason | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1008  | Patient Reason | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1010  | Cancer | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1011  | Occupational Therapy Evaluation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1012  | Patient Provider Interaction | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1018  | Psych Visit for Family Psychotherapy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1022  | Physical Therapy Evaluation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1023  | Behavioral or Neuropsych Assessment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1026  | Radiation Treatment Management | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1027  | Chemotherapy Administration | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1028  | Standardized Pain Assessment Tool | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1090  | Moderate or Severe LVSD | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1091  | Left Ventricular Systolic Dysfunction | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1092  | Moderate or Severe | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1134  | Ejection Fraction | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1139  | ACE Inhibitor or ARB or ARNI | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1140  | Patient Reason for ACE Inhibitor or ARB Decline | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1141  | Psychoanalysis | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1151  | Renal Failure Due to ACE Inhibitor | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1170  | Tobacco User | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1174  | Beta Blocker Therapy | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1176  | Heart Rate | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1177  | Allergy to Beta Blocker Therapy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1178  | Intolerance to Beta Blocker Therapy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1184  | Beta Blocker Therapy for LVSD | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1187  | Group Psychotherapy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1189  | Tobacco Non User | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1190  | Tobacco Use Cessation Pharmacotherapy | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1193  | Cardiac Pacer | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1211  | Allergy to ACE Inhibitor or ARB | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1212  | Intolerance to ACE Inhibitor or ARB | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1240  | Annual Wellness Visit | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1241  | Acute and Subacute Iridocyclitis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1251  | Macular Exam | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1259  | Limited Life Expectancy | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1278  | Tobacco Use Screening | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1283  | Level of Severity of Retinopathy Findings | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1285  | Ophthalmological Services | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1320  | Macular Edema Findings Present | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1332  | Cognitive Assessment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1333  | Cup to Disc Ratio | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1334  | Optic Disc Exam for Structural Abnormalities | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1409  | Burn Confined to Eye and Adnexa | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1410  | Cataract Secondary to Ocular Disorders | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1411  | Cataract Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1412  | Cataract Congenital | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1413  | Cataract Mature or Hypermature | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1414  | Cataract Posterior Polar | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1415  | Certain Types of Iridocyclitis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1416  | Chronic Iridocyclitis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1417  | Cloudy Cornea | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1418  | Corneal Edema | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1419  | Disorders of Cornea Including Corneal Opacity | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1423  | Glaucoma | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1424  | Hereditary Corneal Dystrophies | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1426  | Hypotony of Eye | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1427  | Injury to Optic Nerve and Pathways | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1428  | Central Corneal Ulcer | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1430  | Open Wound of Eyeball | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1432  | Pathologic Myopia | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1433  | Posterior Lenticonus | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1438  | Retrolental Fibroplasias | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1443  | Traumatic Cataract | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1444  | Uveitis | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1445  | Vascular Disorders of Iris and Ciliary Body | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1446  | Visual Field Defects | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1448  | Amblyopia | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1450  | Choroidal Degenerations | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1451  | Choroidal Detachment | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1452  | Choroidal Hemorrhage and Rupture | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1453  | Degeneration of Macula and Posterior Pole | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1454  | Degenerative Disorders of Globe | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1455  | Diabetic Macular Edema | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1457  | Disorders of Optic Chiasm | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1458  | Disorders of Visual Cortex | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1459  | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1460  | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1461  | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1462  | Hereditary Choroidal Dystrophies | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1463  | Hereditary Retinal Dystrophies | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1465  | Nystagmus and Other Irregular Eye Movements | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1466  | Optic Atrophy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1467  | Optic Neuritis | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1468  | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1469  | Other Background Retinopathy and Retinal Vascular Changes | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1471  | Other Disorders of Optic Nerve | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1473  | Other Endophthalmitis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1475  | Prior Penetrating Keratoplasty | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1477  | Purulent Endophthalmitis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1478  | Retinal Detachment with Retinal Defect | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1479  | Retinal Vascular Occlusion | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1480  | Other Proliferative Retinopathy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1482  | Separation of Retinal Layers | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1483  | Visual Acuity 20/40 or Better | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1489  | ACE Inhibitor or ARB or ARNI Ingredient | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1491  | Major Depressive Disorder Active | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1492  | Psych Visit Diagnostic Evaluation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1493  | Beta Blocker Therapy Ingredient | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1496  | Psych Visit Psychotherapy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1530  | Speech and Hearing Evaluation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1558  | Morgagnian Cataract | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1559  | Macular Scar of Posterior Polar | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1560  | Best Corrected Visual Acuity Exam Using Snellen Chart | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1561  | Medications for Above Normal BMI | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1562  | Medications for Below Normal BMI | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1563  | Underweight | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1566  | Adult Depression Medications | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1567  | Adolescent Depression Medications | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1568  | Follow Up for Adult Depression | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1569  | Follow Up for Adolescent Depression | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1570  | Referral for Adolescent Depression | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1571  | Referral for Adult Depression | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1572  | High Intensity Statin Therapy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1573  | LDL Cholesterol | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1574  | Low Intensity Statin Therapy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1575  | Moderate Intensity Statin Therapy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1576  | Outpatient Encounters for Preventive Care | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1578  | Follow Up Within 4 Weeks | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1580  | Referral to Primary Care or Alternate Provider | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1581  | Lifestyle Recommendation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1582  | Patient Declined | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1583  | Referral or Counseling for Alcohol Consumption | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1584  | Hospice Care Ambulatory | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.3000  | Metformin | active | 2019-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.319  | Prostate Cancer | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.320  | Bone Scan | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.326  | Primary Open Angle Glaucoma | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.327  | Diabetic Retinopathy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.353  | End Stage Renal Disease | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.362  | Asthma | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.366  | Arrhythmia | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.367  | Atrioventricular Block | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.368  | Cardiac Pacer in Situ | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.369  | Coronary Artery Disease No MI | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.370  | Hypotension | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.371  | Cardiac Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.376  | Heart Failure | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.378  | Pregnancy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.398  | Prostate Cancer Treatment | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.399  | Salvage Therapy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.401  | Prostate Specific Antigen Test | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.403  | Initial Myocardial Infarction | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.412  | Bradycardia | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.451  | Pain Warranting Further Investigation for Prostate Cancer | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.471  | Bilateral Oophorectomy | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.485  | Chemotherapy | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.509  | Tobacco Use Cessation Counseling | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1498  | Medications for Above Normal BMI | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1499  | Medications for Below Normal BMI | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1519  | Follow Up for Above Normal BMI | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1523  | Follow Up for Above Normal BMI | active | 2017-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1524  | Follow Up for BMI Outside Normal Parameters | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1525  | Follow Up for Above Normal BMI | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1526  | Follow Up for Above Normal BMI | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1527  | Referrals Where Weight Assessment May Occur | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1528  | Follow Up for Below Normal BMI | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1549  | Follow Up for Below Normal BMI | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1550  | Follow Up for Below Normal BMI | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1551  | Follow Up for Below Normal BMI | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1578  | Palliative Care | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1579  | Palliative or Hospice Care | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1608  | Encounter to Document Medications | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1609  | Encounter to Document Medications | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1610  | Referrals Where Weight Assessment May Occur | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1751  | Encounter to Evaluate BMI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1834  | Encounter to Document Medications | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1917  | Encounter to Document Medications | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.695  | Encounter to Evaluate BMI | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.885  | Encounter to Evaluate BMI | active | 2018-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.886  | Encounter to Evaluate BMI | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1475  | Referral to Primary Care or Alternate Provider | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1476  | Pharmacologic Therapy for Hypertension | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1482  | Laboratory Tests for Hypertension | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1497  | Encounter to Screen for Blood Pressure | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1508  | Lifestyle Recommendation | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1509  | Weight Reduction Recommended | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1510  | Weight Reduction Recommended | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1511  | Dietary Recommendations | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1512  | Dietary Recommendations | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1514  | Dietary Recommendations | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1515  | Dietary Recommendations | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1516  | Exercise Class | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1518  | Recommendation to Increase Physical Activity | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1537  | Follow Up Within 4 Weeks | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1538  | Encounter to Screen for Depression | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1914  | Encounter to Screen for Depression | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1915  | Encounter to Screen for Depression | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1916  | Encounter to Screen for Depression | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1918  | Encounter to Screen for Blood Pressure | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.192  | Encounter to Screen for Blood Pressure | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1920  | Encounter to Screen for Blood Pressure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2387  | Overweight or Obese | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2388  | Underweight | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2395  | Finding of Hypertension | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2462  | Laboratory Tests for Hypertension | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2466  | Dental Tooth Extraction | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.259  | Diagnosis of Hypertension | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.261  | Diagnosis of Hypertension | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.263  | Diagnosis of Hypertension | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.467  | Follow Up for Adolescent Depression | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.468  | Follow Up for Adult Depression | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.469  | Adolescent Depression Medications | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.470  | Adult Depression Medications | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.537  | Referral for Adolescent Depression | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.538  | Referral for Adult Depression | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.791  | Patient Declined | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.805  | Weight Reduction Recommended | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.810  | Recommendation to Increase Physical Activity | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.823  | Referral or Counseling for Alcohol Consumption | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6366.117  | Absence of Cervix | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1250  | Major Surgical Procedure | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1668  | CABG Surgeries | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1743  | General or Neuraxial Anesthesia | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1940  | Immunocompromised Conditions | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2262  | CABG Surgeries | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2328  | Immunocompromised Conditions I10 | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2343  | Immunocompromised Conditions | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2363  | Creatinine Lab Test | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.3011  | Acute Myocardial Infarction | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.3024  | Acute Myocardial Infarction | active | 2016-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307  | Encounter Inpatient | active | 2020-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.335  | Bone Marrow Transplant | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.336  | Bone Marrow Transplant | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.404  | Bone Marrow Transplant | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.623  | Acute Myocardial Infarction | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.694  | CABG Surgeries | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.737  | PCI | active | 2018-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.747  | Endotracheal Intubation | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.128  | Bipolar Disorder | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.2433  | Delivery | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.2435  | HBsAg | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.246  | Personality Disorder Emotionally Labile | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.247  | Personality Disorder Emotionally Labile | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.248  | Personality Disorder Emotionally Labile | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.249  | Personality Disorder Emotionally Labile | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.254  | Dysthymia | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.256  | Dysthymia | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.257  | Dysthymia | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.262  | Deceased | active | 2014-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.263  | PHQ 9 and PHQ 9M Tools | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.269  | Hepatitis B | active | 2017-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.271  | Hepatitis B | active | 2017-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.272  | Hepatitis B | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.273  | Live Birth or Delivery | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.274  | Live Birth or Delivery I10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.275  | Live Birth or Delivery | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.277  | Delivery | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.278  | Delivery - Diagnosis | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.279  | HBsAg | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.281  | HBsAg | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.43  | Bipolar Disorder | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.44  | Bipolar Disorder | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.45  | Bipolar Disorder | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.82  | Delivery | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.11.721  | Deceased | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.11.723  | PHQ-9 Tool | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.2.1000  | Estimated Glomerular Filtration Rate | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.2.1002  | Urine Albumin Creatinine Ratio | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.3.1000  | Estimated Glomerular Filtration Rate | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.3.1007  | Urine Albumin Creatinine Ratio | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1000  | Strabismic Amblyopia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1001  | Strabismic Amblyopia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1002  | Refractive Amblyopia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1003  | Refractive Amblyopia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1004  | Routine Ophthalmological Examination | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1005  | Pediatric Best Corrected Visual Acuity Exam | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1006  | LogMAR Visual Acuity Exam | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1007  | Aphakia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1008  | Aphakia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1009  | Infantile and Juvenile Cataract | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1010  | Infantile and Juvenile Cataract | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1011  | Congenital Corneal or Anterior Segment Conditions | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1012  | Congenital Corneal or Anterior Segment Conditions | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1013  | Eyelid or Orbital Conditions | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1014  | Eyelid or Orbital Conditions | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1015  | Coloboma of Optic Disc | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1016  | Coloboma of Optic Disc | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1017  | Hemorrhage of Optic Nerve Sheath | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1018  | Hemorrhage of Optic Nerve Sheath | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1019  | Optic Nerve Hypoplasia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1020  | Optic Nerve Hypoplasia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1021  | Disorder of Visual Cortex Due to Underlying Condition | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1022  | Disorder of Visual Cortex Due to Underlying Condition | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1023  | Cortical Blindness | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1024  | Cortical Blindness | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1025  | Congenital Condition of Retina | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1026  | Congenital Condition of Retina | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1000  | Strabismic Amblyopia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1001  | Refractive Amblyopia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1002  | Routine Ophthalmological Examination | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1003  | Pediatric Best Corrected Visual Acuity Exam | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1004  | LogMAR Visual Acuity Exam | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1005  | Aphakia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1006  | Infantile and Juvenile Cataract | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1007  | Congenital Corneal or Anterior Segment Conditions | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1008  | Eyelid or Orbital Conditions | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1009  | Coloboma of Optic Disc | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1010  | Hemorrhage of Optic Nerve Sheath | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1011  | Optic Nerve Hypoplasia | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1012  | Disorder of Visual Cortex Due to Underlying Condition | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1013  | Cortical Blindness | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1014  | Congenital Condition of Retina | active | 2019-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.6.2  | Allergy and Intolerance Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.6.8  | Severity | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.7.2  | Problem Type (SNOMEDCT) | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.7.4  | Problem | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.11  | Medication Product Form | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.7  | SPL Drug Route of Administration Terminology | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.9  | Body Site Value Set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.16  | Medication Brand Name | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.17  | Medication Clinical General Drug | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.18  | Medication Drug Class | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.22  | CVX Vaccines Administered Complete Set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.28  | Procedure | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.60  | Social History Type (SCT) | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.62  | Vital Sign Result Type | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.64  | Medication Fill Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.68  | Problem Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.2.575  | Race Categories | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.3.155  | Care Team Category | active | 2024-06 |
us.nlm.vsac | R4 | http://hl7.org/fhir/ValueSet/event-timing  | EventTiming | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.40.2.48.1  | Detailed Ethnicity Including Absence Reasons | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.40.2.48.3  | Ethnicity Categories | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.24.7.14  | Clinically Important Bacteria and Fungi | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.24.7.280  | NHSNGenotypicTests | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.24.7.281  | Bacterial Skin Commensals | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1066  | Healthcare Provider Taxonomy | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3180  | NHSNInsertionSiteCode | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3181  | NHSNRoleOfPerformerCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3182  | NHSNReasonForInsertionCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3183  | NHSNSkinPreparationCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3184  | NHSNSterileBarrierCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3185  | NHSNCatheterTypeCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3194  | NHSNSignificantPathogenCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3195  | NHSNCriterionOfDiagnosisCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3196  | NHSNInfectionConditionCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3234  | NHSNPopulationCategoryCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3247  | NHSNTimingCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3248  | NHSNEligibilityCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3249  | NHSNSpecimenTypeCode | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3283  | NHSNOrganismASTCode | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3360  | NHSNAntimicrobialAgentAURPCode | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3361  | NHSNRouteOfAdministrationAURPCode | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591  | Payer Type | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3595  | NHSNPopulationSummaryReportTypeCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6007  | NHSNVascularAccessTypeCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6008  | NHSNSuspectedSourceTypeCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6042  | NHSNVascularAccessSiteCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6051  | NHSNClosureTechniqueCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6074  | NHSNStaphAureusTestResults | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7160  | NHSNStaphAureusSpecificTest | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7214  | NHSNSameDayOutcomeMeasure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7215  | NHSNInfectionFirstReportedSource | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7232  | NHSNRaceCategory | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7233  | NHSNPreviousPatientLocation | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7237  | NHSNBloodCollectionLocation | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7238  | NHSNPreviousFacility | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7239  | NHSNContraindicationType | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7240  | NHSNCarbaTestMethod | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7241  | NHSNCarbaDetectType | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7242  | NHSNCdiffTestMethod | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7338  | NHSNStartOrContinuation | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7353  | NHSNSummaryBloodProductUsage | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.836  | Race | active | 2012-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.837  | Ethnicity | active | 2012-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.877  | Detailed Ethnicity | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.13883.3.3157.4067  | MRI of the Breast | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.13883.3.3157.4068  | MRI of the Breast | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.13883.3.3157.4069  | Intraspinal Abscess | active | 2022-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.113883.3.67.1.101.3.2444  | Major Depression Including Remission | active | 2021-02 |
fhir.argonaut.questionnaire | R3 | CapabilityStatement/adaptive-questionnaire-service  | Argonaut Adaptive Questionnaire Service CapabilityStatement | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | CapabilityStatement/answerbank  | Argonaut Answerbank CapabilityStatement | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | CapabilityStatement/argo-questionnaire-provider-ehr  | Argonaut Argo Questionnaire Provider Ehr CapabilityStatement | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | CapabilityStatement/assessmentbank  | Argonaut Assessmentbank CapabilityStatement | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | ImplementationGuide/argonaut.us.questionnaire-1.0.0  | Argonaut Questionnaire | draft | |
fhir.argonaut.questionnaire | R3 | OperationDefinition/next-question  | Argonaut Next Question Operation | draft | 2018-08 |
fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-audit-c  | Alcohol Use Disorder Identification Test - Consumption [AUDIT-C] | draft | 2019-02 |
fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-dast  | Drug Abuse Screening Test-10 [DAST-10] | draft | 2018-07 |
fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-housing  | Housing Questions | draft | 2018-07 |
fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-phq9  | Patient Health Questionnaire (PHQ-9) | draft | 2018-07 |
fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-sampler  | Argonaut Questionnaire Sampler | draft | 2018-07 |
fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-context-type-value  | context-type-value | draft | 2018-12 |
fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-context-type  | context-type | active | 2018-12 |
fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-context  | context | draft | 2018-12 |
fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-publisher  | questionnaire_publisher | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-status  | questionnaire_status | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-title  | questionnaire_title | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-version  | questionnaire_version | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-author  | questionnaireresponse_author | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-context  | questionnaireresponse_context | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-patient  | questionnaireresponse_patient | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-questionnaire  | questionnaireresponse_questionnaire | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-source  | questionnaireresponse_source | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-status  | questionnaireresponse_status | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | SearchParameter/patient-birthdate  | patient_birthdate | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | StructureDefinition/argo-adap-questionnaireresponse  | Argonaut Adaptive QuestionnaireResponse Profile | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | StructureDefinition/argo-questionnaire-valueset  | Argonaut Questionnaire Contained ValueSet Profile | active | 2018-05 |
fhir.argonaut.questionnaire | R3 | StructureDefinition/argo-questionnaire  | Argonaut Questionnaire Profile | active | 2018-04 |
fhir.argonaut.questionnaire | R3 | StructureDefinition/argo-questionnaireresponse  | Argonaut QuestionnaireResponse Profile | active | 2018-04 |
fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-itemOrder  | Argonaut Questionnaire Item Order Extension | active | 2019-02 |
fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-multipleAnd  | Argonaut SearchParameter Multiple AND Extension | active | 2018-04 |
fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-multipleOr  | Argonaut SearchParameter Multiple OR Extension | active | 2018-04 |
fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-responsePeriod  | Argonaut QuestionnaireResponse Response Period Extension | active | 2018-04 |
fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-timeLimit  | Argonaut Questionnaire Time Limit Extension | active | 2018-02 |
XIG built as of 24 Jun 2025. Found 77087 resources in 1235 packages.